1<!DOCTYPE html><html lang="en" class="geist_a71539c9-module__T19VSG__variable geist_mono_8d43a2aa-module__8Li5zG__variable"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/797e433ab948586e-s.p.29207c2f.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/_next/static/media/caa3a2e1cccd8315-s.p.3b6cae6d.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" imageSrcSet="/_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=640&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 640w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=750&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 750w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=828&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 828w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=1080&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1080w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=1200&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1200w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=1920&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1920w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=2048&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 2048w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=3840&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 3840w" imageSizes="100vw"/><link rel="preload" as="image" href="/images/Lytix_logo-01.svg?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/><link rel="preload" as="image" imageSrcSet="/_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=640&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 640w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=750&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 750w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=828&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 828w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=1080&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1080w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=1200&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1200w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=1920&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1920w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=2048&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 2048w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=3840&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 3840w" imageSizes="100vw"/><link rel="stylesheet" href="/_next/static/chunks/34d933785a17edf3.css?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" data-precedence="next"/><link rel="stylesheet" href="/_next/static/chunks/0411afbfdea66498.css?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/d598f1f652e2d146.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/>
1<script src="/_next/static/chunks/b3ec756f2bdab7eb.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" async=""></script>
1<script src="/_next/static/chunks/ada2ad5975a89c4c.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" async=""></script>
1<script src="/_next/static/chunks/4fa395d360c87cc3.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" async=""></script>
1<script src="/_next/static/chunks/turbopack-902c09f4fbcd1789.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" async=""></script>
1<script src="/_next/static/chunks/ebf919d846f5972d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" async=""></script>
1<script src="/_next/static/chunks/8771e1f26e328b78.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" async=""></script>
1<script src="/_next/static/chunks/bbb5ca06253c0a46.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" async=""></script>
1<script src="/_next/static/chunks/a72f8f12bd2db44d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" async=""></script>
1<script src="/_next/static/chunks/d96012bcfc98706a.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" async=""></script>
1<script src="/_next/static/chunks/73e3194f06db260e.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" async=""></script>
1<meta name="next-size-adjust" content=""/><title>Lytix Biopharma | Oncolytic Immunotherapy</title><meta name="description" content="Lytix Biopharma is developing first-in-class oncolytic molecule therapies that kill cancer with direct and abscopal tumor effects. Redefining the standard of care in the neoadjuvant setting."/><meta name="author" content="Lytix Biopharma"/><meta name="keywords" content="oncology,immunotherapy,cancer treatment,ruxotemitide,LTX-315,neoadjuvant,biopharma,oncolytic"/><meta property="og:title" content="Lytix Biopharma | Oncolytic Immunotherapy"/><meta property="og:description" content="Developing first-in-class oncolytic molecule therapies that kill cancer with direct and abscopal tumor effects."/><meta property="og:site_name" content="Lytix Biopharma"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Lytix Biopharma | Oncolytic Immunotherapy"/><meta name="twitter:description" content="Developing first-in-class oncolytic molecule therapies that kill cancer with direct and abscopal tumor effects."/><link rel="icon" href="/favicon.ico?favicon.0b3bf435.ico" sizes="256x256" type="image/x-icon"/><link rel="icon" href="/icon.svg?icon.2e980a04.svg" sizes="any" type="image/svg+xml"/>
1<script type="application/ld+json">{"@context":"https://schema.org","@type":"ItemList","itemListElement":[{"@type":"SiteNavigationElement","position":1,"name":"About","description":"About Lytix Biopharma","url":"https://www.lytixbiopharma.com/about"},{"@type":"SiteNavigationElement","position":2,"name":"Science","description":"Scientific approach and publications","url":"https://www.lytixbiopharma.com/science"},{"@type":"SiteNavigationElement","position":3,"name":"Pipeline","description":"Clinical and pre-clinical pipeline","url":"https://www.lytixbiopharma.com/pipeline"},{"@type":"SiteNavigationElement","position":4,"name":"Clinical Trials","description":"Ongoing clinical trials","url":"https://www.lytixbiopharma.com/clinical-trials"},{"@type":"SiteNavigationElement","position":5,"name":"Partnerships","description":"Strategic partnerships","url":"https://www.lytixbiopharma.com/partnerships"},{"@type":"SiteNavigationElement","position":6,"name":"Investors","description":"Investor overview and financial information","url":"https://www.lytixbiopharma.com/investors/overview"},{"@type":"SiteNavigationElement","position":7,"name":"News","description":"Latest news and press releases","url":"https://www.lytixbiopharma.com/news"}]}</script>
1<script src="/_next/static/chunks/a6dad97d9634a72d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" noModule=""></script>
1</head><body class="font-sans antialiased"><div hidden=""><!--$--><!--/$--></div><div class="fixed inset-0 z-[1] overflow-hidden pointer-events-none isolate" aria-hidden="true"><div class="absolute inset-0 w-full h-[130vh]" style="transform:translateY(0px)"><img alt="" decoding="async" data-nimg="fill" class="object-cover opacity-[0.12] mix-blend-multiply" style="position:absolute;height:100%;width:100%;left:0;top:0;right:0;bottom:0;color:transparent" sizes="100vw" srcSet="/_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=640&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 640w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=750&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 750w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=828&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 828w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=1080&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1080w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=1200&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1200w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=1920&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1920w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=2048&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 2048w, /_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=3840&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 3840w" src="/_next/image?url=%2Fimages%2Flytix%20ribbon%202.webp&w=3840&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/></div><div class="absolute top-0 right-0 w-[60%] h-[50%] rounded-full opacity-40" style="background:radial-gradient(circle, rgba(31, 166, 163, 0.15) 0%, transparent 60%);transform:translateY(0px);filter:blur(80px)"></div></div><header class="fixed top-0 left-0 right-0 z-50 transition-all duration-300 bg-transparent"><nav class="container mx-auto px-4 lg:px-8"><div class="flex h-18 items-center justify-between"><a class="flex items-center gap-2.5 group" href="/"><img alt="Lytix Biopharma" width="180" height="52" decoding="async" data-nimg="1" class="h-13 w-auto" style="color:transparent" src="/images/Lytix_logo-01.svg?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/></a><div class="hidden xl:flex items-center"><nav aria-label="Main" data-orientation="horizontal" dir="ltr" data-slot="navigation-menu" data-viewport="false" class="group/navigation-menu relative flex max-w-max flex-1 items-center justify-center"><div style="position:relative"><ul data-orientation="horizontal" data-slot="navigation-menu-list" class="group flex flex-1 list-none items-center gap-0 justify-start" dir="ltr"><li data-slot="navigation-menu-item" class="relative"><a class="data-[active=true]:focus:bg-accent data-[active=true]:hover:bg-accent data-[active=true]:bg-accent/50 data-[active=true]:text-accent-foreground hover:bg-accent hover:text-accent-foreground focus:bg-accent focus:text-accent-foreground focus-visible:ring-ring/50 [&_svg:not([class*='text-'])]:text-muted-foreground flex flex-col gap-1 rounded-sm p-2 text-sm transition-all outline-none focus-visible:ring-[3px] focus-visible:outline-1 [&_svg:not([class*='size-'])]:size-4 group inline-flex h-9 w-max items-center justify-center rounded-md text-sm font-medium focus:bg-accent focus:text-accent-foreground disabled:pointer-events-none disabled:opacity-50 data-[state=open]:hover:bg-accent data-[state=open]:text-accent-foreground data-[state=open]:focus:bg-accent data-[state=open]:bg-accent/50 focus-visible:ring-ring/50 outline-none transition-[color,box-shadow] focus-visible:ring-[3px] focus-visible:outline-1 bg-transparent px-1.5 py-1.5 text-lytix-navy hover:bg-lytix-ice/50 hover:text-lytix-teal-dark" data-slot="navigation-menu-link" data-radix-collection-item="" href="/">Home</a></li><li data-slot="navigation-menu-item" class="relative"><a class="group inline-flex h-9 w-max items-center justify-center rounded-md bg-background px-4 py-2 text-sm font-medium hover:bg-accent hover:text-accent-foreground focus:bg-accent focus:text-accent-foreground disabled:pointer-events-none disabled:opacity-50 data-[state=open]:hover:bg-accent data-[state=open]:text-accent-foreground data-[state=open]:focus:bg-accent data-[state=open]:bg-accent/50 focus-visible:ring-ring/50 outline-none transition-[color,box-shadow] focu
1s-visible:ring-[3px] focus-visible:outline-1 group flex items-center bg-transparent px-1.5 py-1.5 text-sm text-lytix-navy hover:bg-lytix-ice/50 hover:text-lytix-teal-dark data-[state=open]:bg-lytix-ice/50" id="radix-_R_4lb_-trigger-radix-_R_9klb_" data-state="closed" aria-expanded="false" aria-controls="radix-_R_4lb_-content-radix-_R_9klb_" data-slot="navigation-menu-trigger" data-radix-collection-item="" href="/about">About<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-down relative top-[1px] ml-0.5 size-3 transition duration-300 group-data-[state=open]:rotate-180" aria-hidden="true"><path d="m6 9 6 6 6-6"></path></svg></a></li><li data-slot="navigation-menu-item" class="relative"><a class="group inline-flex h-9 w-max items-center justify-center rounded-md bg-background px-4 py-2 text-sm font-medium hover:bg-accent hover:text-accent-foreground focus:bg-accent focus:text-accent-foreground disabled:pointer-events-none disabled:opacity-50 data-[state=open]:hover:bg-accent data-[state=open]:text-accent-foreground data-[state=open]:focus:bg-accent data-[state=open]:bg-accent/50 focus-visible:ring-ring/50 outline-none transition-[color,box-shadow] focus-visible:ring-[3px] focus-visible:outline-1 group flex items-center bg-transparent px-1.5 py-1.5 text-sm text-lytix-navy hover:bg-lytix-ice/50 hover:text-lytix-teal-dark data-[state=open]:bg-lytix-ice/50" id="radix-_R_4lb_-trigger-radix-_R_dklb_" data-state="closed" aria-expanded="false" aria-controls="radix-_R_4lb_-content-radix-_R_dklb_" data-slot="navigation-menu-trigger" data-radix-collection-item="" href="/science">Science<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-down relative top-[1px] ml-0.5 size-3 transition duration-300 group-data-[state=open]:rotate-180" aria-hidden="true"><path d="m6 9 6 6 6-6"></path></svg></a></li><li data-slot="navigation-menu-item" class="relative"><a class="data-[active=true]:focus:bg-accent data-[active=true]:hover:bg-accent data-[active=true]:bg-accent/50 data-[active=true]:text-accent-foreground hover:bg-accent hover:text-accent-foreground focus:bg-accent focus:text-accent-foreground focus-visible:ring-ring/50 [&_svg:not([class*='text-'])]:text-muted-foreground flex flex-col gap-1 rounded-sm p-2 text-sm transition-all outline-none focus-visible:ring-[3px] focus-visible:outline-1 [&_svg:not([class*='size-'])]:size-4 group inline-flex h-9 w-max items-center justify-center rounded-md text-sm font-medium focus:bg-accent focus:text-accent-foreground disabled:pointer-events-none disabled:opacity-50 data-[state=open]:hover:bg-accent data-[state=open]:text-accent-foreground data-[state=open]:focus:bg-accent data-[state=open]:bg-accent/50 focus-visible:ring-ring/50 outline-none transition-[color,box-shadow] focus-visible:ring-[3px] focus-visible:outline-1 bg-transparent px-1.5 py-1.5 text-lytix-navy hover:bg-lytix-ice/50 hover:text-lytix-teal-dark" data-slot="navigation-menu-link" data-radix-collection-item="" href="/pipeline">Pipeline</a></li><li data-slot="navigation-menu-item" class="relative"><a class="data-[active=true]:focus:bg-accent data-[active=true]:hover:bg-accent data-[active=true]:bg-accent/50 data-[active=true]:text-accent-foreground hover:bg-accent hover:text-accent-foreground focus:bg-accent focus:text-accent-foreground focus-visible:ring-ring/50 [&_svg:not([class*='text-'])]:text-muted-foreground flex flex-col gap-1 rounded-sm p-2 text-sm transition-all outline-none focus-visible:ring-[3px] focus-visible:outline-1 [&_svg:not([class*='size-'])]:size-4 group inline-flex h-9 w-max items-center justify-center rounded-md text-sm font-medium focus:bg-accent focus:text-accent-foreground disabled:pointer-events-none disabled:opacity-50 data-[state=open]:hover:bg-accent data-[state=open]:text-accent-foreground data-[state=open]:focus:bg-accent data-[state=open]:bg-accent/50 focus-visible:ring-ring/50 outline-none transition-[color,box-shadow] focu
1s-visible:ring-[3px] focus-visible:outline-1 bg-transparent px-1.5 py-1.5 text-lytix-navy hover:bg-lytix-ice/50 hover:text-lytix-teal-dark" data-slot="navigation-menu-link" data-radix-collection-item="" href="/clinical-trials">Clinical Trials</a></li><li data-slot="navigation-menu-item" class="relative"><a class="data-[active=true]:focus:bg-accent data-[active=true]:hover:bg-accent data-[active=true]:bg-accent/50 data-[active=true]:text-accent-foreground hover:bg-accent hover:text-accent-foreground focus:bg-accent focus:text-accent-foreground focus-visible:ring-ring/50 [&_svg:not([class*='text-'])]:text-muted-foreground flex flex-col gap-1 rounded-sm p-2 text-sm transition-all outline-none focus-visible:ring-[3px] focus-visible:outline-1 [&_svg:not([class*='size-'])]:size-4 group inline-flex h-9 w-max items-center justify-center rounded-md text-sm font-medium focus:bg-accent focus:text-accent-foreground disabled:pointer-events-none disabled:opacity-50 data-[state=open]:hover:bg-accent data-[state=open]:text-accent-foreground data-[state=open]:focus:bg-accent data-[state=open]:bg-accent/50 focus-visible:ring-ring/50 outline-none transition-[color,box-shadow] focus-visible:ring-[3px] focus-visible:outline-1 bg-transparent px-1.5 py-1.5 text-lytix-navy hover:bg-lytix-ice/50 hover:text-lytix-teal-dark" data-slot="navigation-menu-link" data-radix-collection-item="" href="/partnerships">Partnerships</a></li><li data-slot="navigation-menu-item" class="relative"><a class="group inline-flex h-9 w-max items-center justify-center rounded-md bg-background px-4 py-2 text-sm font-medium hover:bg-accent hover:text-accent-foreground focus:bg-accent focus:text-accent-foreground disabled:pointer-events-none disabled:opacity-50 data-[state=open]:hover:bg-accent data-[state=open]:text-accent-foreground data-[state=open]:focus:bg-accent data-[state=open]:bg-accent/50 focus-visible:ring-ring/50 outline-none transition-[color,box-shadow] focus-visible:ring-[3px] focus-visible:outline-1 group flex items-center bg-transparent px-1.5 py-1.5 text-sm text-lytix-navy hover:bg-lytix-ice/50 hover:text-lytix-teal-dark data-[state=open]:bg-lytix-ice/50" id="radix-_R_4lb_-trigger-radix-_R_tklb_" data-state="closed" aria-expanded="false" aria-controls="radix-_R_4lb_-content-radix-_R_tklb_" data-slot="navigation-menu-trigger" data-radix-collection-item="" href="/investors/overview">Investors<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-down relative top-[1px] ml-0.5 size-3 transition duration-300 group-data-[state=open]:rotate-180" aria-hidden="true"><path d="m6 9 6 6 6-6"></path></svg></a></li><li data-slot="navigation-menu-item" class="relative"><a class="data-[active=true]:focus:bg-accent data-[active=true]:hover:bg-accent data-[active=true]:bg-accent/50 data-[active=true]:text-accent-foreground hover:bg-accent hover:text-accent-foreground focus:bg-accent focus:text-accent-foreground focus-visible:ring-ring/50 [&_svg:not([class*='text-'])]:text-muted-foreground flex flex-col gap-1 rounded-sm p-2 text-sm transition-all outline-none focus-visible:ring-[3px] focus-visible:outline-1 [&_svg:not([class*='size-'])]:size-4 group inline-flex h-9 w-max items-center justify-center rounded-md text-sm font-medium focus:bg-accent focus:text-accent-foreground disabled:pointer-events-none disabled:opacity-50 data-[state=open]:hover:bg-accent data-[state=open]:text-accent-foreground data-[state=open]:focus:bg-accent data-[state=open]:bg-accent/50 focus-visible:ring-ring/50 outline-none transition-[color,box-shadow] focus-visible:ring-[3px] focus-visible:outline-1 bg-transparent px-1.5 py-1.5 text-lytix-navy hover:bg-lytix-ice/50 hover:text-lytix-teal-dark" data-slot="navigation-menu-link" data-radix-collection-item="" href="/news">News</a></li></ul></div></nav></div><div class="hidden xl:flex items-center gap-4"><a href="/contact"><button data-slot="button" data-variant="default" data-size="default" class="inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md text-sm disabled:pointer-events-none disabled:opacity-50 [&_svg]:pointer-events-none [&_svg:not([class*='
1size-'])]:size-4 shrink-0 [&_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive h-9 py-2 has-[>svg]:px-3 bg-lytix-navy-deep hover:bg-lytix-cyan hover:text-lytix-navy text-white font-semibold px-6 shadow-md hover:shadow-lg transition-all">Contact Us</button></a></div><div class="xl:hidden"><button data-slot="sheet-trigger" data-variant="ghost" data-size="icon" class="inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md text-sm font-medium transition-all disabled:pointer-events-none disabled:opacity-50 [&_svg]:pointer-events-none [&_svg:not([class*='size-'])]:size-4 shrink-0 [&_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive hover:text-accent-foreground dark:hover:bg-accent/50 size-9 h-10 w-10 text-lytix-navy hover:bg-lytix-ice" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8lb_" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-menu h-6 w-6" aria-hidden="true"><path d="M4 5h16"></path><path d="M4 12h16"></path><path d="M4 19h16"></path></svg><span class="sr-only">Toggle menu</span></button></div></div></nav></header><main class="min-h-screen"><div class="flex flex-col"><section class="relative flex flex-col md:block md:min-h-screen overflow-hidden z-[2] bg-white"><div class="absolute inset-0 hidden md:block"><img alt="Lytix Biopharma - Transforming cancer treatment" decoding="async" data-nimg="fill" class="object-cover object-center" style="position:absolute;height:100%;width:100%;left:0;top:0;right:0;bottom:0;color:transparent" sizes="100vw" srcSet="/_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=640&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 640w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=750&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 750w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=828&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 828w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=1080&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1080w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=1200&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1200w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=1920&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1920w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=2048&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 2048w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=3840&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 3840w" src="/_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=3840&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/><div class="absolute inset-0 bg-gradient-to-r from-white via-white/50 to-transparent"></div></div><div class="relative w-full h-[55vh] md:hidden"><img alt="Lytix Biopharma - Transforming cancer treatment" decoding="async" data-nimg="fill" class="object-cover object-[70%_15%]" style="position:absolute;height:100%;width:100%;left:0;top:0;right:0;bottom:0;color:transparent" sizes="100vw" srcSet="/_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=640&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 640w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=750&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 750w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=828&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 828w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=1080&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1080w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=1200&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1200w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=1920&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1920w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=2048&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 2048w, /_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=3840&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 3840w" src="/_next/image?url=%2Fimages%2Flytix%20hero%20people%20main.webp&w=3840&q=90&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/><div class="absolute inset-0 bg-gradient-to-t from-white via-white/10 to-transparent"></div></div><div class="container mx-auto px-4 lg:px-8 py-10 md:pt-24 md:pb-16 relative z-10 md:min-
1h-screen md:flex md:items-center"><div class="max-w-2xl text-center md:text-left mx-auto md:mx-0"><div class="space-y-6 md:space-y-8"><h1 class="animate-fade-up opacity-0 stagger-1 text-4xl md:text-5xl lg:text-6xl font-bold leading-tight tracking-tight text-[#40525C] drop-shadow-sm">Oncolytic Molecules that Kill Cancer with Direct & Abscopal Tumor Effects</h1><p class="animate-fade-up opacity-0 stagger-2 text-xl md:text-3xl font-semibold text-[#40525C] leading-snug max-w-xl mx-auto md:mx-0">Neoadjuvant Immunotherapy with Durable Responses Approaching Registrational Studies</p></div></div></div><div class="hidden md:block absolute bottom-8 left-1/2 -translate-x-1/2 animate-fade-up stagger-6 opacity-0"><div class="animate-float"><div class="w-7 h-11 rounded-full border-2 border-lytix-navy/30 flex items-start justify-center p-2 bg-white/30 backdrop-blur-sm shadow-lg"><div class="w-1.5 h-3 bg-lytix-teal rounded-full animate-bounce"></div></div></div></div></section><section class="py-16 md:py-32 bg-white relative overflow-hidden group/section z-[2]"><div class="absolute top-0 left-0 w-1/3 h-full bg-gradient-to-r from-lytix-ice/50 to-transparent"></div><div class="container mx-auto px-4 lg:px-8 relative z-10"><div class="grid lg:grid-cols-2 gap-8 lg:gap-20 items-center"><div class="order-2 lg:order-1 animate-slide-left stagger-2"><div class="relative rounded-2xl overflow-hidden shadow-2xl hover:shadow-3xl transition-shadow duration-500 group"><img alt="Oncolytic molecule therapy visualization" loading="lazy" width="800" height="500" decoding="async" data-nimg="1" class="w-full h-auto object-cover group-hover:scale-105 transition-transform duration-700" style="color:transparent" srcSet="/_next/image?url=%2Fimages%2Fribbon%20hero%202%20homepage.webp&w=828&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1x, /_next/image?url=%2Fimages%2Fribbon%20hero%202%20homepage.webp&w=1920&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 2x" src="/_next/image?url=%2Fimages%2Fribbon%20hero%202%20homepage.webp&w=1920&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/><div class="absolute inset-0 bg-gradient-to-t from-lytix-navy/20 to-transparent opacity-0 group-hover:opacity-100 transition-opacity duration-500"></div></div></div><div class="order-1 lg:order-2 space-y-6 animate-slide-right stagger-1"><div class="mb-14"><div class="w-12 h-1 bg-lytix-teal rounded-full mb-4"></div><span class="text-xl md:text-2xl font-black uppercase tracking-[0.25em] text-lytix-teal-dark block">Our Mission</span></div><h2 class="text-4xl md:text-5xl lg:text-6xl font-bold leading-tight text-[#40525C]">Lytix Biopharma is Redefining the Standard of Care in the Neoadjuvant Setting</h2><p class="text-lg text-lytix-navy/90 leading-relaxed">Lytix Biopharma is developing a pipeline of oncolytic molecule therapies that treat both superficial and deep-seated tumors. Our focus is to re-define the standard of care in the neoadjuvant (pre-surgery) setting, through providing patients with first-in-class, first-line immunotherapies that kill cancer with direct and abscopal tumor effects.</p><p class="text-lg text-lytix-navy/90 leading-relaxed">Our mission is to deliver transformative medicines that work in synergy with immune checkpoint inhibitors, to offer patients the best outcomes in the pre-surgical setting with a full immune system intact.</p></div></div></div></section><section class="py-16 md:py-32 bg-lytix-light relative overflow-hidden"><div class="absolute inset-0 molecular-pattern opacity-50"></div><div class="container mx-auto px-4 lg:px-8 relative z-10"><div class="grid lg:grid-cols-2 gap-8 lg:gap-20 items-center"><div class="space-y-6 animate-slide-left stagger-1"><div class="mb-14"><div class="w-12 h-1 bg-lytix-coral rounded-full mb-4"></div><span class="text-xl md:text-2xl font-black uppercase tracking-[0.25em] text-lytix-coral block">Our Science</span></div><h2 class="text-4xl md:text-5xl lg:text-6xl font-bold leading-tight text-[#40525C]">Our Oncolytic Molecule Drugs Overcome Immunosuppression Within the Tumor Microenvironment</h2><p class="text-lg text-lytix-navy/90 leading-relaxed">Lytix Biopharma has developed a groundbreaking oncolytic molecule platform that overcomes the limitations of current immunotherapies and delivers durable anti-tumor responses and intratumoral administration.</p><p class="text-lg text-lytix-navy/90 leading-relaxed">
1Our drugs destroy the membranes of cancer cells, releasing both tumor antigens and potent immunostimulatory molecules that initiate a broad immune cell response. The resulting immune cell infiltration into the tumor microenvironment delivers broad and durable anti-tumor immunity.</p><a href="/science"><button data-slot="button" data-variant="link" data-size="default" class="inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md font-medium transition-all disabled:pointer-events-none disabled:opacity-50 [&_svg]:pointer-events-none [&_svg:not([class*='size-'])]:size-4 shrink-0 [&_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive underline-offset-4 hover:underline h-9 py-2 has-[>svg]:px-3 px-0 text-lytix-teal-dark hover:text-lytix-teal text-lg group/btn">Discover Our Science<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-right ml-1 h-5 w-5 group-hover/btn:translate-x-2 transition-transform duration-300" aria-hidden="true"><path d="m9 18 6-6-6-6"></path></svg></button></a></div><div class="animate-slide-right stagger-2"><div class="relative rounded-2xl overflow-hidden shadow-2xl group hover:shadow-3xl transition-shadow duration-500"><img alt="Cancer cell and immune system interaction" loading="lazy" width="800" height="500" decoding="async" data-nimg="1" class="w-full h-auto object-cover group-hover:scale-105 transition-transform duration-700" style="color:transparent" srcSet="/_next/image?url=%2Fimages%2Fribbon%20x%20cancer%20cell%20interaction%20hero%203.webp&w=828&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1x, /_next/image?url=%2Fimages%2Fribbon%20x%20cancer%20cell%20interaction%20hero%203.webp&w=1920&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 2x" src="/_next/image?url=%2Fimages%2Fribbon%20x%20cancer%20cell%20interaction%20hero%203.webp&w=1920&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/><div class="absolute inset-0 bg-gradient-to-t from-lytix-coral/20 to-transparent opacity-0 group-hover:opacity-100 transition-opacity duration-500"></div></div></div></div></div></section><section class="pt-16 md:pt-32 pb-12 bg-white relative z-[2]"><div class="container mx-auto px-4 lg:px-8"><div class="text-center max-w-3xl mx-auto mb-16 space-y-4 animate-fade-up stagger-1"><h2 class="text-4xl md:text-5xl lg:text-6xl font-bold leading-tight text-[#40525C]">Our Pipeline is Led by Ruxotemitide, Rapidly Approaching Registrational Studies</h2></div><div class="relative animate-scale-up stagger-2"><div class="overflow-hidden max-h-[320px] md:max-h-[350px]"><div class="hidden md:block overflow-x-auto"><div class="min-w-[800px] bg-white rounded-t-2xl border-2 border-b-0 border-lytix-ice shadow-xl overflow-hidden"><div class="grid grid-cols-7 gap-4 p-6 bg-lytix-navy text-white text-xs font-bold uppercase tracking-wider"><div class="col-span-2">Asset</div><div class="text-center">Preclinical</div><div class="text-center">Phase I</div><div class="text-center">Phase II</div><div class="text-center">Phase III</div><div class="text-center">Partner</div></div><div class="grid grid-cols-7 gap-4 items-center py-5 px-6 border-b border-lytix-ice hover:bg-lytix-light/50 transition-colors"><div class="col-span-2"><div class="flex items-center gap-2 mb-1"><div class="w-2.5 h-2.5 rounded-full bg-lytix-teal relative"><span class="absolute inset-0 rounded-full bg-lytix-teal animate-ping opacity-40"></span></div><p class="font-bold text-lytix-teal-dark">Ruxotemitide (LTX-315)</p></div><p class="text-sm text-lytix-navy/85 ml-4">Neoadjuvant resectable melanoma</p></div><div class="col-span-4 px-2"><div class="relative h-4 bg-lytix-ice rounded-full overflow-hidden"><div class="absolute inset-0 grid grid-cols-4 z-10 pointer-events-none"><span class="border-r-2 border-white"></span><span class="border-r-2 border-white"></span><span class="border-r-2 border-white"></span><span></span></div><div class="pipeline-bar-fill absolute left-0 top-0 h-full w-[75%] bg-gradient-to-r from-lytix-teal via-lytix-teal to-lytix-cyan rounded-full overflow-hidden"><span class="pipeline-shine"></span></div></div></div><div class="text-center"><span class="badge-shine inline-flex items-center justify-center px-3 py-1.5 rounded-full bg-lytix-coral/10 text-lytix-coral font-semibold text-xs border border-lytix-coral/20 text-center">Seeking Partners</span></div></div><div class="grid grid-cols-7 gap-4 items-center py-5 px-6 border-b border-lytix-ice hover:bg-lytix-light/50 transition-colors"><div class="col-span-2"><div class="flex items-center gap-2 mb-1"><div class="w-2.5 h-2.5 rounded-full bg-lytix-navy-deep relative"><span class="absolute inset-0 rounded-full bg-lytix-navy-deep animate-ping opacity-40"></span></div><p class="font-bold text-lytix-navy-deep">LTX-401</p></div><p class="text-sm text-lytix-navy/85 ml-4">Deep-seated solid tumors</p></div><div class="col-span-4 px-2"><div class="relative h-4 bg-lytix-ice rounded-full overflow-hidden"><div class="absolute inset-0 grid grid-cols-4 z-10 pointer-events-none"><span class="border-r-2 border-white"></span><span class="border-r-2 border-white"></span><span class="border-r-2 border-white"></span><span></span></div><div class="pipeline-bar-fill absolute left-0 top-0 h-full w-[21%] bg-gradient-to-r from-lytix-teal to-lytix-cyan rounded-full overflow-hidden" style="animation-delay:0.3s"><span class="pipeline-shine"></span></div></div></div><div class="text-center"><span class="badge-shine inline-flex items-center px-3 py-1.5 rounded-full bg-lytix-coral/10 text-lytix-coral font-semibold text-xs border border-lytix-coral/20">Seeking Partners</span></div></div><div class="grid grid-cols-7 gap-4 items-center py-5 px-6 border-b border-lytix-ice"><div class="col-span-2"><div class="flex items-center gap-2 mb-1"><div class="w-2.5 h-2.5 rounded-full bg-lytix-teal/50"></div><p class="font-bold text-lytix-teal-dark/60">More Pipeline Assets...</p></div></div><div class="col-span-4 px-2"><div class="h-4 bg-lytix-ice rounded-full"></div></div><div class="text-center"></div></div></div></div><div class="md:hidden flex flex-col gap-4 bg-white rounded-t-2xl border-2 border-b-0 border-lytix-ice shadow-xl p-4 sm:p-6 pb-24"><div class="border-2 border-lytix-ice rounded-xl p-5 bg-gradient-to-br from-white to-lytix-light shadow-sm"><div class="flex flex-col gap-3 mb-4"><div><div class="flex items-center gap-2 mb-1"><div class="w-2.5 h-2.5 rounded-full bg-lytix-teal relative flex-shrink-0"><span class="absolute inset-0 rounded-full bg-lytix-teal animate-ping opacity-40"></span></div><p class="font-bold text-lytix-teal-dark text-lg leading-tight">Ruxotemitide (LTX-315)</p></div><p class="text-sm text-lytix-navy/85 ml-4">Neoadjuvant resectable melanoma</p></div><div class="ml-4"><span class="badge-shine inline-flex items-center justify-center px-3 py-1 rounded-full bg-lytix-coral/10 text-lytix-coral font-semibold text-xs border border-lytix-coral/20">Seeking Partners</span></div></div><div class="mt-5 bg-white p-3 rounded-lg border border-lytix-ice"><div class="flex justify-between text-[10px] font-bold text-lytix-navy/60 uppercase tracking-wider mb-2 px-1"><span>Pre</span><span>I</span><span>II</span><span>III</span></div><div class="relative h-4 bg-lytix-ice rounded-full overflow-hidden"><div class="absolute inset-0 grid grid-cols-4 z-10 pointer-events-none"><span class="border-r-2 border-white"></span><span class="border-r-2 border-white"></span><span class="border-r-2 border-white"></span><span></span></div><div class="pipeline-bar-fill absolute left-0 top-0 h-full w-[75%] bg-gradient-to-r from-lytix-teal via-lytix-teal to-lytix-cyan rounded-full overflow-hidden"><span class="pipeline-shine"></span></div></div></div></div><div class="border-2 border-lytix-ice rounded-xl p-5 bg-gradient-to-br from-white to-lytix-light shadow-sm"><div class="flex flex-col gap-3 mb-4"><div><div class="flex items-center gap-2 mb-1"><div class="w-2.5 h-2.5 rounded-full bg-lytix-navy-deep relative flex-shrink-0"><span class="absolute inset-0 rounded-full bg-lytix-navy-deep animate-ping opacity-40"></span></div><p class="font-bold text-lytix-navy-deep text-lg leading-tight">LTX-401</p></div><p class="text-sm text-lytix-navy/85 ml-4">Deep-seated solid tumors</p></div><div class="ml-4"><span class="badge-shine inline-flex items-center px-3 py-1 rounded-full bg-lytix-coral/10 text-lytix-coral font-semibold text-xs border border-lytix-coral/20">Seeking Partners</span></div></div><div class="mt-5 bg-white p-3 rounded-lg border border-lytix-ice"><div class="flex justify-between text-[10px] font-bold text-lytix-navy/60 uppercase tracking-wider mb-2 px-1"><span>Pre</span><span>I</span><span>II</span><span>III</span></div><div class="relative h-4 bg-lytix-ice rounded-full overflow-hidden"><div class="absolute inset-0 grid grid-cols-4 z-10 pointer-events-none"><span class="border-r-2 border-white"></span><span class="border-r-2 border-white"></span><span class="border-r-2 border-white"></span><span></span></div><div class="pipeline-bar-fill absolute left-0 top-0 h-full w-[21%] bg-gradient-to-r from-lytix-teal to-lytix-cyan rounded-full overflow-hidden" style="animation-delay:0.3s"><span class="pipeline-shine"></span></div></div></div></div><div class="border border-lytix-ice rounded-xl p-5 bg-lytix-light/30 opacity-40"><div class="flex items-center gap-2"><div class="w-2.5 h-2.5 rounded-full bg-lytix-teal/50"></div><p class="font-bold text-lytix-teal-dark/60">More Pipeline Assets...</p></div></div></div></div><div class="absolute bottom-0 left-0 right-0 h-32 bg-gradient-to-t from-white via-white to-transparent pointer-events-none"></div><div class="absolute bottom-0 left-0 right-0 flex justify-center pb-2 z-10"><a href="/pipeline"><button data-slot="button" data-variant="default" data-size="lg" class="inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium disabled:pointer-events-none disabled:opacity-50 [&_svg]:pointer-events-none [&_svg:not([class*='
1size-'])]:size-4 shrink-0 [&_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive bg-primary hover:bg-primary/90 h-10 rounded-md px-6 has-[>svg]:px-4 btn-lytix-gradient text-white shadow-xl hover:shadow-2xl hover:scale-105 transition-all">View Full Pipeline<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-arrow-right ml-2 h-5 w-5" aria-hidden="true"><path d="M5 12h14"></path><path d="m12 5 7 7-7 7"></path></svg></button></a></div></div></div></section><section class="py-16 md:py-32 bg-navy-gradient text-white relative overflow-hidden"><div class="absolute inset-0 tech-grid opacity-10"></div><div class="absolute top-0 right-0 w-1/2 h-full bg-gradient-to-l from-lytix-teal/10 to-transparent"></div><div class="container mx-auto px-4 lg:px-8 relative z-10"><div class="mb-12 animate-slide-left"><div class="w-12 h-1 bg-lytix-cyan rounded-full mb-4"></div><span class="text-xl md:text-2xl font-black uppercase tracking-[0.25em] text-lytix-cyan block">Clinical Trials</span></div><div class="grid lg:grid-cols-2 gap-8 lg:gap-20 items-center"><div class="space-y-6 animate-slide-left stagger-1"><h2 class="text-4xl md:text-5xl lg:text-6xl font-bold leading-tight">Learn More About Our Deep <span class="text-lytix-cyan">Clinical Trial Validation</span></h2><p class="text-lg text-white/90 leading-relaxed">Lytix Biopharma has completed multiple Phase 2 trials, and is currently enrolling patients in an investigator-led Phase 2 study, NeoLIPA which is evaluating ruxotemitide (formerly LTX-315) in combination with pembrolizumab in resectable melanoma patients in the neoadjuvant setting.</p><a href="/clinical-trials"><button data-slot="button" data-variant="default" data-size="lg" class="inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium disabled:pointer-events-none disabled:opacity-50 [&_svg]:pointer-events-none [&_svg:not([class*='size-'])]:size-4 shrink-0 [&_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive h-10 rounded-md px-6 has-[>svg]:px-4 bg-lytix-teal hover:bg-lytix-cyan hover:text-lytix-navy text-white shadow-lg hover:shadow-xl transition-all hover:scale-[1.02]">Explore Clinical Trials<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-arrow-right ml-2 h-5 w-5" aria-hidden="true"><path d="M5 12h14"></path><path d="m12 5 7 7-7 7"></path></svg></button></a></div><div class="animate-slide-right stagger-2"><div class="relative rounded-2xl overflow-hidden shadow-2xl border border-white/10 group hover:shadow-lytix-cyan/20 hover:shadow-3xl transition-all duration-500"><img alt="Scientific visualization" loading="lazy" width="800" height="500" decoding="async" data-nimg="1" class="w-full h-auto object-cover group-hover:scale-105 transition-transform duration-700" style="color:transparent" srcSet="/_next/image?url=%2Fimages%2Forb%201.webp&w=828&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1x, /_next/image?url=%2Fimages%2Forb%201.webp&w=1920&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 2x" src="/_next/image?url=%2Fimages%2Forb%201.webp&w=1920&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/><div class="absolute inset-0 bg-gradient-to-tr from-lytix-cyan/20 to-transparent opacity-0 group-hover:opacity-100 transition-opacity duration-500"></div></div></div></div></div></section><section class="py-16 md:py-32 bg-white relative z-[2]"><div class="container mx-auto px-4 lg:px-8"><div class="grid lg:grid-cols-2 gap-8 lg:gap-20 items-center"><div class="order-2 lg:order-1 animate-slide-left stagger-2"><div class="relative rounded-2xl overflow-hidden shadow-2xl group hover:shadow-3xl transition-shadow duration-500"><img alt="Medical professional - Partnership opportunities" loading="lazy" width="800" height="500" decoding="async" data-nimg="1" class="w-full h-auto object-cover group-hover:scale-105 transition-transform duration-700" style="color:transparent" srcSet="/_next/image?url=%2Fimages%2Fdoctor%20hero.webp&w=828&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1x, /_next/image?url=%2Fimages%2Fdoctor%20hero.webp&w=1920&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 2x" src="/_next/image?url=%2Fimages%2Fdoctor%20hero.webp&w=1920&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/></div></div><div class="order-1 lg:order-2 space-y-6 animate-slide-right stagger-1"><div class="mb-14"><div class="w-12 h-1 bg-lytix-teal rounded-full mb-4"></div><span class="text-xl md:text-2xl font-black uppercase tracking-[0.25em] text-lytix-teal-dark block">Partnerships</span></div><h2 class="text-4xl md:text-5xl lg:text-6xl font-bold leading-tight text-lytix-navy">Our Partnering Strategy is Built to Deliver <span class="text-lytix-coral">Commercial Success</span></h2><p class="text-lg text-lytix-navy/90 leading-relaxed">Interested in learning more about our assets? At Lytix Biopharma we are open to discu
1ssions on co-development and outlicensing opportunities.</p><div class="p-6 rounded-xl bg-gradient-to-br from-lytix-ice to-white border border-lytix-teal/20 hover:border-lytix-teal/40 hover:shadow-lg transition-all duration-300"><div class="flex items-center gap-2 mb-4"><div class="w-2 h-2 rounded-full bg-lytix-teal animate-pulse"></div><h4 class="font-semibold text-lg text-lytix-navy">Current Partnership</h4></div><div class="flex items-center justify-center py-3 mb-4 bg-white rounded-lg border border-lytix-ice"><img alt="Verrica Pharmaceuticals" loading="lazy" width="180" height="70" decoding="async" data-nimg="1" class="h-auto w-[160px] object-contain" style="color:transparent" srcSet="/_next/image?url=%2Fimages%2Fverrica-logo.png&w=256&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 1x, /_next/image?url=%2Fimages%2Fverrica-logo.png&w=384&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7 2x" src="/_next/image?url=%2Fimages%2Fverrica-logo.png&w=384&q=75&dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/></div><p class="text-lytix-navy/90 mb-3 text-sm leading-relaxed">Dermatology indications only. Completed Phase 2 study of ruxotemitide (LTX-315, VP-315) in basal cell carcinoma with <strong class="text-lytix-navy">51% complete response rate</strong>.</p><a href="https://newsweb.oslobors.no/message/659147" target="_blank" rel="noopener noreferrer" class="inline-flex items-center text-lytix-coral hover:text-lytix-raspberry font-medium transition-colors group/link text-sm">See latest positive results<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-external-link ml-2 h-4 w-4 group-hover/link:rotate-12 transition-transform" aria-hidden="true"><path d="M15 3h6v6"></path><path d="M10 14 21 3"></path><path d="M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1-2-2V8a2 2 0 0 1 2-2h6"></path></svg></a></div><a href="/partnerships"><button data-slot="button" data-variant="link" data-size="default" class="inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md font-medium transition-all disabled:pointer-events-none disabled:opacity-50 [&_svg]:pointer-events-none [&_svg:not([class*='size-'])]:size-4 shrink-0 [&_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive underline-offset-4 hover:underline h-9 py-2 has-[>svg]:px-3 px-0 text-lytix-teal-dark hover:text-lytix-teal text-lg group/btn">Learn About Partnerships<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-right ml-1 h-5 w-5 group-hover/btn:translate-x-2 transition-transform duration-300" aria-hidden="true"><path d="m9 18 6-6-6-6"></path></svg></button></a></div></div></div></section><section class="py-16 md:py-32 bg-lytix-light relative overflow-hidden"><div class="absolute inset-0 molecular-pattern opacity-30"></div><div class="container mx-auto px-4 lg:px-8 relative z-10"><div class="text-center max-w-3xl mx-auto mb-16 space-y-4 animate-fade-up stagger-1"><div class="mb-14 flex flex-col items-center"><div class="w-12 h-1 bg-lytix-teal rounded-full mb-4"></div><span class="text-xl md:text-2xl font-black uppercase tracking-[0.25em] text-lytix-teal-dark block -mr-[0.25em]">News</span></div><h2 class="text-4xl md:text-5xl lg:text-6xl font-bold leading-tight text-lytix-navy">Latest Press Releases</h2></div><div class="grid md:grid-cols-3 gap-6 mb-12"><div data-slot="card" class="text-card-foreground flex flex-col gap-6 rounded-xl border py-6 shadow-sm card-hover border-lytix-ice bg-white group animate-scale-up stagger-1"><div data-slot="card-header" class="@container/card-header grid auto-rows-min grid-rows-[auto_auto] items-start gap-2 px-6 has-data-[slot=card-action]:grid-cols-[1fr_auto] [.border-b]:pb-6"><div data-slot="card-description" class="text-sm text-lytix-navy/80">Sep 3, 2026</div><div data-slot="card-title" class="font-semibold text-lg leading-tight text-lytix-navy group-hover:text-lytix-teal-dark transition-colors duration-300">Lytix Biopharma ASA: Grant of share options to management and key personnel</div></div>
1<div data-slot="card-content" class="px-6"><p class="text-lytix-navy/85 text-sm line-clamp-3 mb-4">Lytix Biopharma ASA: Grant of share options to management and key personnel</p><a href="https://newsweb.oslobors.no/message/681627" target="_blank" rel="noopener noreferrer" class="inline-flex items-center text-lytix-teal-dark hover:text-lytix-teal font-medium text-sm group/link">Read More<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-right ml-1 h-4 w-4 group-hover/link:translate-x-1 transition-transform" aria-hidden="true"><path d="m9 18 6-6-6-6"></path></svg></a></div></div><div data-slot="card" class="text-card-foreground flex flex-col gap-6 rounded-xl border py-6 shadow-sm card-hover border-lytix-ice bg-white group animate-scale-up stagger-2"><div data-slot="card-header" class="@container/card-header grid auto-rows-min grid-rows-[auto_auto] items-start gap-2 px-6 has-data-[slot=card-action]:grid-cols-[1fr_auto] [.border-b]:pb-6"><div data-slot="card-description" class="text-sm text-lytix-navy/80">Sep 2, 2026</div><div data-slot="card-title" class="font-semibold text-lg leading-tight text-lytix-navy group-hover:text-lytix-teal-dark transition-colors duration-300">Lytix Biopharma ASA: Mandatory notification of trade by primary insider</div></div><div data-slot="card-content" class="px-6"><p class="text-lytix-navy/85 text-sm line-clamp-3 mb-4">Lytix Biopharma ASA: Mandatory notification of trade by primary insider</p><a href="https://newsweb.oslobors.no/message/681499" target="_blank" rel="noopener noreferrer" class="inline-flex items-center text-lytix-teal-dark hover:text-lytix-teal font-medium text-sm group/link">Read More<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-right ml-1 h-4 w-4 group-hover/link:translate-x-1 transition-transform" aria-hidden="true"><path d="m9 18 6-6-6-6"></path></svg></a></div></div><div data-slot="card" class="text-card-foreground flex flex-col gap-6 rounded-xl border py-6 shadow-sm card-hover border-lytix-ice bg-white group animate-scale-up stagger-3"><div data-slot="card-header" class="@container/card-header grid auto-rows-min grid-rows-[auto_auto] items-start gap-2 px-6 has-data-[slot=card-action]:grid-cols-[1fr_auto] [.border-b]:pb-6"><div data-slot="card-description" class="text-sm text-lytix-navy/80">Aug 26, 2026</div><div data-slot="card-title" class="font-semibold text-lg leading-tight text-lytix-navy group-hover:text-lytix-teal-dark transition-colors duration-300">Lytix Biopharma Q2 2026: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma, Marking Defining Milestone</div></div><div data-slot="card-content" class="px-6"><p class="text-lytix-navy/85 text-sm line-clamp-3 mb-4">Lytix Biopharma Q2 2026: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma, Marking Defining Milestone</p><a href="https://newsweb.oslobors.no/message/680938" target="_blank" rel="noopener noreferrer" class="inline-flex items-center text-lytix-teal-dark hover:text-lytix-teal font-medium text-sm group/link">Read More<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-right ml-1 h-4 w-4 group-hover/link:translate-x-1 transition-transform" aria-hidden="true"><path d="m9 18 6-6-6-6"></path></svg></a></div></div></div><div class="text-center animate-fade-up stagger-5"><a href="/news"><button data-slot="button" data-variant="outline" data-size="lg" class="inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium disabled:pointer-events-none disabled:opacity-50 [&_svg]:pointer-events-none [&_svg:not([class*='
1size-'])]:size-4 shrink-0 [&_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive bg-background shadow-xs dark:bg-input/30 dark:border-input dark:hover:bg-input/50 h-10 rounded-md px-6 has-[>svg]:px-4 border-2 border-lytix-teal text-lytix-teal-dark hover:bg-lytix-teal hover:text-white hover:scale-[1.02] transition-all">View All Press Releases<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-arrow-right ml-2 h-5 w-5" aria-hidden="true"><path d="M5 12h14"></path><path d="m12 5 7 7-7 7"></path></svg></button></a></div></div></section></div><!--$--><!--/$--></main><footer class="bg-navy-gradient text-white relative overflow-hidden z-[2]"><div class="absolute top-0 left-0 w-96 h-96 bg-lytix-teal/5 rounded-full blur-3xl"></div><div class="absolute bottom-0 right-0 w-80 h-80 bg-lytix-coral/5 rounded-full blur-3xl"></div><div class="h-1.5 bg-gradient-to-r from-lytix-teal via-lytix-cyan to-lytix-gold"></div><div class="container mx-auto px-4 lg:px-8 relative z-10"><div class="py-12 md:py-20 grid grid-cols-1 md:grid-cols-2 lg:grid-cols-5 gap-12"><div class="lg:col-span-1"><a class="inline-block mb-8 group" href="/"><img alt="Lytix Biopharma" loading="lazy" width="150" height="44" decoding="async" data-nimg="1" class="h-11 w-auto brightness-0 invert group-hover:opacity-80 transition-opacity" style="color:transparent" src="/images/Lytix_logo-01.svg?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7"/></a><p class="text-sm text-lytix-ice/60 leading-relaxed mb-8 font-light">Oncolytic Molecules that Kill Cancer with Direct & Abscopal Tumor Effects</p><div class="flex items-center gap-2 text-lytix-ice/50 text-sm mb-6"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-map-pin h-4 w-4 text-lytix-teal" aria-hidden="true"><path d="M20 10c0 4.993-5.539 10.193-7.399 11.799a1 1 0 0 1-1.202 0C9.539 20.193 4 14.993 4 10a8 8 0 0 1 16 0"></path><circle cx="12" cy="10" r="3"></circle></svg><span>Oslo, Norway</span></div><div class="flex items-center gap-3"><a href="https://linkedin.com/company/lytix-biopharma?originalSubdomain=no" target="_blank" rel="noopener noreferrer" class="p-3 rounded-xl bg-white/5 hover:bg-lytix-teal text-lytix-cyan hover:text-white transition-all duration-300 hover:scale-110"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-linkedin h-5 w-5" aria-hidden="true"><path d="M16 8a6 6 0 0 1 6 6v7h-4v-7a2 2 0 0 0-2-2 2 2 0 0 0-2 2v7h-4v-7a6 6 0 0 1 6-6z"></path><rect width="4" height="12" x="2" y="9"></rect><circle cx="4" cy="4" r="2"></circle></svg></a><a href="mailto:[email protected]" class="p-3 rounded-xl bg-white/5 hover:bg-lytix-teal text-lytix-cyan hover:text-white transition-all duration-300 hover:scale-110"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-mail h-5 w-5" aria-hidden="true"><path d="m22 7-8.991 5.727a2 2 0 0 1-2.009 0L2 7"></path><rect x="2" y="4" width="20" height="16" rx="2"></rect></svg></a></div></div><div><h4 class="text-xs font-black uppercase tracking-[0.2em] mb-6 text-lytix-gold">Company</h4><ul class="space-y-3"><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/about">About</a></li><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/about/management">Management Team</a></li><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/about/board">Board of Directors</a></li><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/about/scientific-advisory">Scientific Advisory Board</a></li></ul></div><div><h4 class="text-xs font-black uppercase tracking-[0.2em] mb-6 text-lytix-gold">Science</h4><ul class="space-y-3"><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/science">Our Science</a></li><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/pipeline">Pipeline</a></li><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/science#publications">Publications</a></li><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/science#posters">Posters</a></li></ul></div><div><h4 class="text-xs font-black uppercase tracking-[0.2em] mb-6 text-lytix-gold">Resources</h4><ul class="space-y-3"><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/clinical-trials">Clinical Trials</a></li><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/news">News</a></li><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/investors/overview">Investor Relations</a></li></ul></div><div><h4 class="text-xs font-black uppercase tracking-[0.2em] mb-6 text-lytix-gold">Connect</h4><ul class="space-y-3"><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/partnerships">Partnerships</a></li><li><a class="text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light" href="/contact">Contact</a></li></ul><div class="mt-8 pt-6 border-t border-white/10"><a class="inline-flex items-center gap-2 text-sm font-bold text-lytix-coral hover:text-lytix-gold transition-all group" href="/partnerships">Partner With Us<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-arrow-right h-4 w-4 group-hover:translate-x-1 transition-transform" aria-hidden="true"><path d="M5 12h14"></path><path d="m12 5 7 7-7 7"></path></svg></a></div></div></div><div class="py-6 border-t border-white/10 flex flex-col md:flex-row items-center justify-between gap-4"><p class="text-xs text-lytix-ice/40 font-light">© <!-- -->2026<!-- --> Lytix Biopharma ASA. All rights reserved.</p><div class="flex items-center gap-6 flex-wrap"><a class="text-xs text-lytix-ice/40 hover:text-lytix-cyan transition-colors font-light" href="/privacy">Privacy Policy</a><button class="text-xs text-lytix-ice/40 hover:text-lytix-cyan transition-colors font-light">Cookies</button><a class="text-xs text-lytix-ice/40 hover:text-lytix-cyan transition-colors font-light" href="/terms">Terms and Conditions</a><a class="text-xs text-lytix-ice/40 hover:text-lytix-cyan transition-colors font-light" href="/disclaimer">Disclaimer</a></div></div></div></footer>
1<script src="/_next/static/chunks/d598f1f652e2d146.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7" id="_R_" async=""></script>
1<script>(self.__next_f=self.__next_f||[]).push([0])</script>
1<script>self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[383255,[\"/_next/static/chunks/ebf919d846f5972d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/8771e1f26e328b78.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/bbb5ca06253c0a46.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/a72f8f12bd2db44d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"SpatialBackdrop\"]\n4:I[845678,[\"/_next/static/chunks/ebf919d846f5972d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/8771e1f26e328b78.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/bbb5ca06253c0a46.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/a72f8f12bd2db44d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"Navbar\"]\n5:I[339756,[\"/_next/static/chunks/d96012bcfc98706a.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/73e3194f06db260e.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"default\"]\n6:I[837457,[\"/_next/static/chunks/d96012bcfc98706a.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/73e3194f06db260e.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"default\"]\nb:I[168027,[],\"default\"]\n:HL[\"/_next/static/chunks/34d933785a17edf3.css?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"style\"]\n:HL[\"/_next/static/chunks/0411afbfdea66498.css?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"style\"]\n:HL[\"/_next/static/media/797e433ab948586e-s.p.29207c2f.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/caa3a2e1cccd8315-s.p.3b6cae6d.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:T4b8,{\"@context\":\"https://schema.org\",\"@type\":\"ItemList\",\"itemListElement\":[{\"@type\":\"SiteNavigationElement\",\"position\":1,\"name\":\"About\",\"description\":\"About Lytix Biopharma\",\"url\":\"https://www.lytixbiopharma.com/about\"},{\"@type\":\"SiteNavigationElement\",\"position\":2,\"name\":\"Science\",\"description\":\"Scientific approach and publications\",\"url\":\"https://www.lytixbiopharma.com/science\"},{\"@type\":\"SiteNavigationElement\",\"position\":3,\"name\":\"Pipeline\",\"description\":\"Clinical and pre-clinical pipeline\",\"url\":\"https://www.lytixbiopharma.com/pipeline\"},{\"@type\":\"SiteNavigationElement\",\"position\":4,\"name\":\"Clinical Trials\",\"description\":\"Ongoing clinical trials\",\"url\":\"https://www.lytixbiopharma.com/clinical-trials\"},{\"@type\":\"SiteNavigationElement\",\"position\":5,\"name\":\"Partnerships\",\"description\":\"Strategic partnerships\",\"url\":\"https://www.lytixbiopharma.com/partnerships\"},{\"@type\":\"SiteNavigationElement\",\"position\":6,\"name\":\"Investors\",\"description\":\"Investor overview and financial information\",\"url\":\"https://www.lytixbiopharma.com/investors/overview\"},{\"@type\":\"SiteNavigationElement\",\"position\":7,\"name\":\"News\",\"description\":\"Latest news and press releases\",\"url\":\"https://www.lytixbiopharma.com/news\"}]}"])</script>
1<script>self.__next_f.push([1,"0:{\"P\":null,\"b\":\"QK16NnX2xhW1zPl-T1Ks_\",\"c\":[\"\",\"index\"],\"q\":\"\",\"i\":false,\"f\":[[[\"\",{\"children\":[\"__PAGE__\",{}]},\"$undefined\",\"$undefined\",true],[[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/chunks/34d933785a17edf3.css?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/chunks/0411afbfdea66498.css?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"}],[\"$\",\"script\",\"script-0\",{\"src\":\"/_next/static/chunks/ebf919d846f5972d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"async\":true,\"nonce\":\"$undefined\"}],[\"$\",\"script\",\"script-1\",{\"src\":\"/_next/static/chunks/8771e1f26e328b78.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"async\":true,\"nonce\":\"$undefined\"}],[\"$\",\"script\",\"script-2\",{\"src\":\"/_next/static/chunks/bbb5ca06253c0a46.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"async\":true,\"nonce\":\"$undefined\"}],[\"$\",\"script\",\"script-3\",{\"src\":\"/_next/static/chunks/a72f8f12bd2db44d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"async\":true,\"nonce\":\"$undefined\"}]],[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"geist_a71539c9-module__T19VSG__variable geist_mono_8d43a2aa-module__8Li5zG__variable\",\"children\":[[\"$\",\"head\",null,{\"children\":[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"$2\"}}]}],[\"$\",\"body\",null,{\"className\":\"font-sans antialiased\",\"children\":[[\"$\",\"$L3\",null,{}],[\"$\",\"$L4\",null,{}],[\"$\",\"main\",null,{\"className\":\"min-h-screen\",\"children\":[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"}],[\"$\",\"div\",null,{\"style\":{\"fontFamily\":\"system-ui,\\\"Segoe UI\\\",Roboto,Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\"\",\"height\":\"100vh\",\"textAlign\":\"center\",\"display\":\"flex\",\"flexDirection\":\"column\",\"alignItems\":\"center\",\"justifyContent\":\"center\"},\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}}],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":{\"display\":\"inline-block\",\"margin\":\"0 20px 0 0\",\"padding\":\"0 23px 0 0\",\"fontSize\":24,\"fontWeight\":500,\"verticalAlign\":\"top\",\"lineHeight\":\"49px\"},\"children\":404}],[\"$\",\"div\",null,{\"style\":{\"display\":\"inline-block\"},\"children\":[\"$\",\"h2\",null,{\"style\":{\"fontSize\":14,\"fontWeight\":400,\"lineHeight\":\"49px\",\"margin\":0},\"children\":\"This page could not be found.\"}]}]]}]}]],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]}],\"$L7\",\"$L8\"]}]]}]]}],{\"children\":[\"$L9\",{},null,false,false]},null,false,false],\"$La\",false]],\"m\":\"$undefined\",\"G\":[\"$b\",[]],\"S\":true}\n"])</script>
1<script>self.__next_f.push([1,"c:I[522016,[\"/_next/static/chunks/ebf919d846f5972d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/8771e1f26e328b78.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/bbb5ca06253c0a46.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/a72f8f12bd2db44d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"\"]\nd:I[605500,[\"/_next/static/chunks/ebf919d846f5972d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/8771e1f26e328b78.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/bbb5ca06253c0a46.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/a72f8f12bd2db44d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"Image\"]\n13:I[611015,[\"/_next/static/chunks/ebf919d846f5972d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/8771e1f26e328b78.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/bbb5ca06253c0a46.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/a72f8f12bd2db44d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"default\"]\n15:I[897367,[\"/_next/static/chunks/d96012bcfc98706a.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/73e3194f06db260e.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"OutletBoundary\"]\n16:\"$Sreact.suspense\"\n18:I[897367,[\"/_next/static/chunks/d96012bcfc98706a.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/73e3194f06db260e.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"ViewportBoundary\"]\n1a:I[897367,[\"/_next/static/chunks/d96012bcfc98706a.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/73e3194f06db260e.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"MetadataBoundary\"]\n"])</script>
1<script>self.__next_f.push([1,"7:[\"$\",\"footer\",null,{\"className\":\"bg-navy-gradient text-white relative overflow-hidden z-[2]\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute top-0 left-0 w-96 h-96 bg-lytix-teal/5 rounded-full blur-3xl\"}],[\"$\",\"div\",null,{\"className\":\"absolute bottom-0 right-0 w-80 h-80 bg-lytix-coral/5 rounded-full blur-3xl\"}],[\"$\",\"div\",null,{\"className\":\"h-1.5 bg-gradient-to-r from-lytix-teal via-lytix-cyan to-lytix-gold\"}],[\"$\",\"div\",null,{\"className\":\"container mx-auto px-4 lg:px-8 relative z-10\",\"children\":[[\"$\",\"div\",null,{\"className\":\"py-12 md:py-20 grid grid-cols-1 md:grid-cols-2 lg:grid-cols-5 gap-12\",\"children\":[[\"$\",\"div\",null,{\"className\":\"lg:col-span-1\",\"children\":[[\"$\",\"$Lc\",null,{\"href\":\"/\",\"className\":\"inline-block mb-8 group\",\"children\":[\"$\",\"$Ld\",null,{\"src\":\"/images/Lytix_logo-01.svg\",\"alt\":\"Lytix Biopharma\",\"width\":150,\"height\":44,\"className\":\"h-11 w-auto brightness-0 invert group-hover:opacity-80 transition-opacity\"}]}],[\"$\",\"p\",null,{\"className\":\"text-sm text-lytix-ice/60 leading-relaxed mb-8 font-light\",\"children\":\"Oncolytic Molecules that Kill Cancer with Direct \u0026 Abscopal Tumor Effects\"}],[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2 text-lytix-ice/50 text-sm mb-6\",\"children\":[[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-map-pin h-4 w-4 text-lytix-teal\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"1r0f0z\",{\"d\":\"M20 10c0 4.993-5.539 10.193-7.399 11.799a1 1 0 0 1-1.202 0C9.539 20.193 4 14.993 4 10a8 8 0 0 1 16 0\"}],[\"$\",\"circle\",\"ilqhr7\",{\"cx\":\"12\",\"cy\":\"10\",\"r\":\"3\"}],\"$undefined\"]}],[\"$\",\"span\",null,{\"children\":\"Oslo, Norway\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center gap-3\",\"children\":[[\"$\",\"a\",null,{\"href\":\"https://linkedin.com/company/lytix-biopharma?originalSubdomain=no\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"p-3 rounded-xl bg-white/5 hover:bg-lytix-teal text-lytix-cyan hover:text-white transition-all duration-300 hover:scale-110\",\"children\":[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-linkedin h-5 w-5\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"c2jq9f\",{\"d\":\"M16 8a6 6 0 0 1 6 6v7h-4v-7a2 2 0 0 0-2-2 2 2 0 0 0-2 2v7h-4v-7a6 6 0 0 1 6-6z\"}],[\"$\",\"rect\",\"mk3on5\",{\"width\":\"4\",\"height\":\"12\",\"x\":\"2\",\"y\":\"9\"}],[\"$\",\"circle\",\"bt5ra8\",{\"cx\":\"4\",\"cy\":\"4\",\"r\":\"2\"}],\"$undefined\"]}]}],[\"$\",\"a\",null,{\"href\":\"mailto:[email protected]\",\"className\":\"p-3 rounded-xl bg-white/5 hover:bg-lytix-teal text-lytix-cyan hover:text-white transition-all duration-300 hover:scale-110\",\"children\":[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-mail h-5 w-5\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"132q7q\",{\"d\":\"m22 7-8.991 5.727a2 2 0 0 1-2.009 0L2 7\"}],[\"$\",\"rect\",\"izxlao\",{\"x\":\"2\",\"y\":\"4\",\"width\":\"20\",\"height\":\"16\",\"rx\":\"2\"}],\"$undefined\"]}]}]]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"text-xs font-black uppercase tracking-[0.2em] mb-6 text-lytix-gold\",\"children\":\"Company\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"li\",\"/about\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/about\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"About\"}]}],[\"$\",\"li\",\"/about/management\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/about/management\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"Management Team\"}]}],[\"$\",\"li\",\"/about/board\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/about/board\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"Board of Directors\"}]}],\"$Le\"]}]]}],\"$Lf\",\"$L10\",\"$L11\"]}],\"$L12\"]}]]}]\n"])</script>
1<script>self.__next_f.push([1,"8:[\"$\",\"$L13\",null,{}]\n9:[\"$\",\"$1\",\"c\",{\"children\":[\"$L14\",null,[\"$\",\"$L15\",null,{\"children\":[\"$\",\"$16\",null,{\"name\":\"Next.MetadataOutlet\",\"children\":\"$@17\"}]}]]}]\na:[\"$\",\"$1\",\"h\",{\"children\":[null,[\"$\",\"$L18\",null,{\"children\":\"$L19\"}],[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$L1a\",null,{\"children\":[\"$\",\"$16\",null,{\"name\":\"Next.Metadata\",\"children\":\"$L1b\"}]}]}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]]}]\n"])</script>
1<script>self.__next_f.push([1,"1c:I[199176,[\"/_next/static/chunks/ebf919d846f5972d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/8771e1f26e328b78.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/bbb5ca06253c0a46.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/a72f8f12bd2db44d.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"default\"]\ne:[\"$\",\"li\",\"/about/scientific-advisory\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/about/scientific-advisory\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"Scientific Advisory Board\"}]}]\nf:[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"text-xs font-black uppercase tracking-[0.2em] mb-6 text-lytix-gold\",\"children\":\"Science\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"li\",\"/science\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/science\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"Our Science\"}]}],[\"$\",\"li\",\"/pipeline\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/pipeline\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"Pipeline\"}]}],[\"$\",\"li\",\"/science#publications\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/science#publications\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"Publications\"}]}],[\"$\",\"li\",\"/science#posters\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/science#posters\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"Posters\"}]}]]}]]}]\n10:[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"text-xs font-black uppercase tracking-[0.2em] mb-6 text-lytix-gold\",\"children\":\"Resources\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"li\",\"/clinical-trials\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/clinical-trials\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"Clinical Trials\"}]}],[\"$\",\"li\",\"/news\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/news\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"News\"}]}],[\"$\",\"li\",\"/investors/overview\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/investors/overview\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"Investor Relations\"}]}]]}]]}]\n"])</script>
1<script>self.__next_f.push([1,"11:[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"text-xs font-black uppercase tracking-[0.2em] mb-6 text-lytix-gold\",\"children\":\"Connect\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"li\",\"/partnerships\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/partnerships\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"Partnerships\"}]}],[\"$\",\"li\",\"/contact\",{\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/contact\",\"className\":\"text-sm text-lytix-ice/60 hover:text-lytix-cyan transition-all duration-200 hover:translate-x-1 inline-block font-light\",\"children\":\"Contact\"}]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-8 pt-6 border-t border-white/10\",\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/partnerships\",\"className\":\"inline-flex items-center gap-2 text-sm font-bold text-lytix-coral hover:text-lytix-gold transition-all group\",\"children\":[\"Partner With Us\",[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-arrow-right h-4 w-4 group-hover:translate-x-1 transition-transform\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"1ays0h\",{\"d\":\"M5 12h14\"}],[\"$\",\"path\",\"xquz4c\",{\"d\":\"m12 5 7 7-7 7\"}],\"$undefined\"]}]]}]}]]}]\n"])</script>
1<script>self.__next_f.push([1,"12:[\"$\",\"div\",null,{\"className\":\"py-6 border-t border-white/10 flex flex-col md:flex-row items-center justify-between gap-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-lytix-ice/40 font-light\",\"children\":[\"© \",2026,\" Lytix Biopharma ASA. All rights reserved.\"]}],[\"$\",\"div\",null,{\"className\":\"flex items-center gap-6 flex-wrap\",\"children\":[[\"$\",\"$Lc\",null,{\"href\":\"/privacy\",\"className\":\"text-xs text-lytix-ice/40 hover:text-lytix-cyan transition-colors font-light\",\"children\":\"Privacy Policy\"}],[\"$\",\"$L1c\",null,{}],[\"$\",\"$Lc\",null,{\"href\":\"/terms\",\"className\":\"text-xs text-lytix-ice/40 hover:text-lytix-cyan transition-colors font-light\",\"children\":\"Terms and Conditions\"}],[\"$\",\"$Lc\",null,{\"href\":\"/disclaimer\",\"className\":\"text-xs text-lytix-ice/40 hover:text-lytix-cyan transition-colors font-light\",\"children\":\"Disclaimer\"}]]}]]}]\n"])</script>
1<script>self.__next_f.push([1,"19:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}]]\n"])</script>
1<script>self.__next_f.push([1,"1d:I[27201,[\"/_next/static/chunks/d96012bcfc98706a.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\",\"/_next/static/chunks/73e3194f06db260e.js?dpl=dpl_2gvvKBTiNhFQso3vRg2C4hPc2Dh7\"],\"IconMark\"]\n17:null\n"])</script>
1<script>self.__next_f.push([1,"1b:[[\"$\",\"title\",\"0\",{\"children\":\"Lytix Biopharma | Oncolytic Immunotherapy\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Lytix Biopharma is developing first-in-class oncolytic molecule therapies that kill cancer with direct and abscopal tumor effects. Redefining the standard of care in the neoadjuvant setting.\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"Lytix Biopharma\"}],[\"$\",\"meta\",\"3\",{\"name\":\"keywords\",\"content\":\"oncology,immunotherapy,cancer treatment,ruxotemitide,LTX-315,neoadjuvant,biopharma,oncolytic\"}],[\"$\",\"meta\",\"4\",{\"property\":\"og:title\",\"content\":\"Lytix Biopharma | Oncolytic Immunotherapy\"}],[\"$\",\"meta\",\"5\",{\"property\":\"og:description\",\"content\":\"Developing first-in-class oncolytic molecule therapies that kill cancer with direct and abscopal tumor effects.\"}],[\"$\",\"meta\",\"6\",{\"property\":\"og:site_name\",\"content\":\"Lytix Biopharma\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",\"9\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"10\",{\"name\":\"twitter:title\",\"content\":\"Lytix Biopharma | Oncolytic Immunotherapy\"}],[\"$\",\"meta\",\"11\",{\"name\":\"twitter:description\",\"content\":\"Developing first-in-class oncolytic molecule therapies that kill cancer with direct and abscopal tumor effects.\"}],[\"$\",\"link\",\"12\",{\"rel\":\"icon\",\"href\":\"/favicon.ico?favicon.0b3bf435.ico\",\"sizes\":\"256x256\",\"type\":\"image/x-icon\"}],[\"$\",\"link\",\"13\",{\"rel\":\"icon\",\"href\":\"/icon.svg?icon.2e980a04.svg\",\"sizes\":\"any\",\"type\":\"image/svg+xml\"}],[\"$\",\"$L1d\",\"14\",{}]]\n"])</script>
1<script>self.__next_f.push([1,"14:[\"$\",\"div\",null,{\"className\":\"flex flex-col\",\"children\":[[\"$\",\"section\",null,{\"className\":\"relative flex flex-col md:block md:min-h-screen overflow-hidden z-[2] bg-white\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute inset-0 hidden md:block\",\"children\":[[\"$\",\"$Ld\",null,{\"src\":\"/images/lytix hero people main.webp\",\"alt\":\"Lytix Biopharma - Transforming cancer treatment\",\"fill\":true,\"className\":\"object-cover object-center\",\"priority\":true,\"quality\":90}],[\"$\",\"div\",null,{\"className\":\"absolute inset-0 bg-gradient-to-r from-white via-white/50 to-transparent\"}]]}],[\"$\",\"div\",null,{\"className\":\"relative w-full h-[55vh] md:hidden\",\"children\":[[\"$\",\"$Ld\",null,{\"src\":\"/images/lytix hero people main.webp\",\"alt\":\"Lytix Biopharma - Transforming cancer treatment\",\"fill\":true,\"className\":\"object-cover object-[70%_15%]\",\"priority\":true,\"quality\":90}],[\"$\",\"div\",null,{\"className\":\"absolute inset-0 bg-gradient-to-t from-white via-white/10 to-transparent\"}]]}],[\"$\",\"div\",null,{\"className\":\"container mx-auto px-4 lg:px-8 py-10 md:pt-24 md:pb-16 relative z-10 md:min-h-screen md:flex md:items-center\",\"children\":[\"$\",\"div\",null,{\"className\":\"max-w-2xl text-center md:text-left mx-auto md:mx-0\",\"children\":[\"$\",\"div\",null,{\"className\":\"space-y-6 md:space-y-8\",\"children\":[[\"$\",\"h1\",null,{\"className\":\"animate-fade-up opacity-0 stagger-1 text-4xl md:text-5xl lg:text-6xl font-bold leading-tight tracking-tight text-[#40525C] drop-shadow-sm\",\"children\":\"Oncolytic Molecules that Kill Cancer with Direct \u0026 Abscopal Tumor Effects\"}],[\"$\",\"p\",null,{\"className\":\"animate-fade-up opacity-0 stagger-2 text-xl md:text-3xl font-semibold text-[#40525C] leading-snug max-w-xl mx-auto md:mx-0\",\"children\":\"Neoadjuvant Immunotherapy with Durable Responses Approaching Registrational Studies\"}]]}]}]}],[\"$\",\"div\",null,{\"className\":\"hidden md:block absolute bottom-8 left-1/2 -translate-x-1/2 animate-fade-up stagger-6 opacity-0\",\"children\":[\"$\",\"div\",null,{\"className\":\"animate-float\",\"children\":[\"$\",\"div\",null,{\"className\":\"w-7 h-11 rounded-full border-2 border-lytix-navy/30 flex items-start justify-center p-2 bg-white/30 backdrop-blur-sm shadow-lg\",\"children\":[\"$\",\"div\",null,{\"className\":\"w-1.5 h-3 bg-lytix-teal rounded-full animate-bounce\"}]}]}]}]]}],[\"$\",\"section\",null,{\"className\":\"py-16 md:py-32 bg-white relative overflow-hidden group/section z-[2]\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute top-0 left-0 w-1/3 h-full bg-gradient-to-r from-lytix-ice/50 to-transparent\"}],[\"$\",\"div\",null,{\"className\":\"container mx-auto px-4 lg:px-8 relative z-10\",\"children\":[\"$\",\"div\",null,{\"className\":\"grid lg:grid-cols-2 gap-8 lg:gap-20 items-center\",\"children\":[[\"$\",\"div\",null,{\"className\":\"order-2 lg:order-1 animate-slide-left stagger-2\",\"children\":[\"$\",\"div\",null,{\"className\":\"relative rounded-2xl overflow-hidden shadow-2xl hover:shadow-3xl transition-shadow duration-500 group\",\"children\":[[\"$\",\"$Ld\",null,{\"src\":\"/images/ribbon hero 2 homepage.webp\",\"alt\":\"Oncolytic molecule therapy visualization\",\"width\":800,\"height\":500,\"className\":\"w-full h-auto object-cover group-hover:scale-105 transition-transform duration-700\"}],[\"$\",\"div\",null,{\"className\":\"absolute inset-0 bg-gradient-to-t from-lytix-navy/20 to-transparent opacity-0 group-hover:opacity-100 transition-opacity duration-500\"}]]}]}],[\"$\",\"div\",null,{\"className\":\"order-1 lg:order-2 space-y-6 animate-slide-right stagger-1\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-14\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-12 h-1 bg-lytix-teal rounded-full mb-4\"}],[\"$\",\"span\",null,{\"className\":\"text-xl md:text-2xl font-black uppercase tracking-[0.25em] text-lytix-teal-dark block\",\"children\":\"Our Mission\"}]]}],[\"$\",\"h2\",null,{\"className\":\"text-4xl md:text-5xl lg:text-6xl font-bold leading-tight text-[#40525C]\",\"children\":\"Lytix Biopharma is Redefining the Standard of Care in the Neoadjuvant Setting\"}],[\"$\",\"p\",null,{\"className\":\"text-lg text-lytix-navy/90 leading-relaxed\",\"children\":\"Lytix Biopharma is developing a pipeline of oncolytic molecule therapies that treat both superficial and deep-seated tumors. Our focus is to re-define the standard of care in the neoadjuvant (pre-surgery) setting, through providing patients with first-in-class, first-line immunotherapies that kill cancer with direct and abscopal tumor effects.\"}],\"$L1e\"]}]]}]}]]}],\"$L1f\",\"$L20\",\"$L21\",\"$L22\",\"$L23\"]}]\n"])</script>
1<script>self.__next_f.push([1,"1e:[\"$\",\"p\",null,{\"className\":\"text-lg text-lytix-navy/90 leading-relaxed\",\"children\":\"Our mission is to deliver transformative medicines that work in synergy with immune checkpoint inhibitors, to offer patients the best outcomes in the pre-surgical setting with a full immune system intact.\"}]\n"])</script>
1<script>self.__next_f.push([1,"1f:[\"$\",\"section\",null,{\"className\":\"py-16 md:py-32 bg-lytix-light relative overflow-hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute inset-0 molecular-pattern opacity-50\"}],[\"$\",\"div\",null,{\"className\":\"container mx-auto px-4 lg:px-8 relative z-10\",\"children\":[\"$\",\"div\",null,{\"className\":\"grid lg:grid-cols-2 gap-8 lg:gap-20 items-center\",\"children\":[[\"$\",\"div\",null,{\"className\":\"space-y-6 animate-slide-left stagger-1\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-14\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-12 h-1 bg-lytix-coral rounded-full mb-4\"}],[\"$\",\"span\",null,{\"className\":\"text-xl md:text-2xl font-black uppercase tracking-[0.25em] text-lytix-coral block\",\"children\":\"Our Science\"}]]}],[\"$\",\"h2\",null,{\"className\":\"text-4xl md:text-5xl lg:text-6xl font-bold leading-tight text-[#40525C]\",\"children\":\"Our Oncolytic Molecule Drugs Overcome Immunosuppression Within the Tumor Microenvironment\"}],[\"$\",\"p\",null,{\"className\":\"text-lg text-lytix-navy/90 leading-relaxed\",\"children\":\"Lytix Biopharma has developed a groundbreaking oncolytic molecule platform that overcomes the limitations of current immunotherapies and delivers durable anti-tumor responses and intratumoral administration.\"}],[\"$\",\"p\",null,{\"className\":\"text-lg text-lytix-navy/90 leading-relaxed\",\"children\":\"Our drugs destroy the membranes of cancer cells, releasing both tumor antigens and potent immunostimulatory molecules that initiate a broad immune cell response. The resulting immune cell infiltration into the tumor microenvironment delivers broad and durable anti-tumor immunity.\"}],[\"$\",\"$Lc\",null,{\"href\":\"/science\",\"children\":[\"$\",\"button\",null,{\"data-slot\":\"button\",\"data-variant\":\"link\",\"data-size\":\"default\",\"className\":\"inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md font-medium transition-all disabled:pointer-events-none disabled:opacity-50 [\u0026_svg]:pointer-events-none [\u0026_svg:not([class*='size-'])]:size-4 shrink-0 [\u0026_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive underline-offset-4 hover:underline h-9 py-2 has-[\u003esvg]:px-3 px-0 text-lytix-teal-dark hover:text-lytix-teal text-lg group/btn\",\"children\":[\"Discover Our Science\",[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-chevron-right ml-1 h-5 w-5 group-hover/btn:translate-x-2 transition-transform duration-300\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"mthhwq\",{\"d\":\"m9 18 6-6-6-6\"}],\"$undefined\"]}]]}]}]]}],[\"$\",\"div\",null,{\"className\":\"animate-slide-right stagger-2\",\"children\":[\"$\",\"div\",null,{\"className\":\"relative rounded-2xl overflow-hidden shadow-2xl group hover:shadow-3xl transition-shadow duration-500\",\"children\":[[\"$\",\"$Ld\",null,{\"src\":\"/images/ribbon x cancer cell interaction hero 3.webp\",\"alt\":\"Cancer cell and immune system interaction\",\"width\":800,\"height\":500,\"className\":\"w-full h-auto object-cover group-hover:scale-105 transition-transform duration-700\"}],[\"$\",\"div\",null,{\"className\":\"absolute inset-0 bg-gradient-to-t from-lytix-coral/20 to-transparent opacity-0 group-hover:opacity-100 transition-opacity duration-500\"}]]}]}]]}]}]]}]\n"])</script>
1<script>self.__next_f.push([1,"20:[\"$\",\"section\",null,{\"className\":\"pt-16 md:pt-32 pb-12 bg-white relative z-[2]\",\"children\":[\"$\",\"div\",null,{\"className\":\"container mx-auto px-4 lg:px-8\",\"children\":[[\"$\",\"div\",null,{\"className\":\"text-center max-w-3xl mx-auto mb-16 space-y-4 animate-fade-up stagger-1\",\"children\":[\"$\",\"h2\",null,{\"className\":\"text-4xl md:text-5xl lg:text-6xl font-bold leading-tight text-[#40525C]\",\"children\":\"Our Pipeline is Led by Ruxotemitide, Rapidly Approaching Registrational Studies\"}]}],[\"$\",\"div\",null,{\"className\":\"relative animate-scale-up stagger-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"overflow-hidden max-h-[320px] md:max-h-[350px]\",\"children\":[[\"$\",\"div\",null,{\"className\":\"hidden md:block overflow-x-auto\",\"children\":[\"$\",\"div\",null,{\"className\":\"min-w-[800px] bg-white rounded-t-2xl border-2 border-b-0 border-lytix-ice shadow-xl overflow-hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"grid grid-cols-7 gap-4 p-6 bg-lytix-navy text-white text-xs font-bold uppercase tracking-wider\",\"children\":[[\"$\",\"div\",null,{\"className\":\"col-span-2\",\"children\":\"Asset\"}],[\"$\",\"div\",null,{\"className\":\"text-center\",\"children\":\"Preclinical\"}],[\"$\",\"div\",null,{\"className\":\"text-center\",\"children\":\"Phase I\"}],[\"$\",\"div\",null,{\"className\":\"text-center\",\"children\":\"Phase II\"}],[\"$\",\"div\",null,{\"className\":\"text-center\",\"children\":\"Phase III\"}],[\"$\",\"div\",null,{\"className\":\"text-center\",\"children\":\"Partner\"}]]}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-7 gap-4 items-center py-5 px-6 border-b border-lytix-ice hover:bg-lytix-light/50 transition-colors\",\"children\":[[\"$\",\"div\",null,{\"className\":\"col-span-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2 mb-1\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-2.5 h-2.5 rounded-full bg-lytix-teal relative\",\"children\":[\"$\",\"span\",null,{\"className\":\"absolute inset-0 rounded-full bg-lytix-teal animate-ping opacity-40\"}]}],[\"$\",\"p\",null,{\"className\":\"font-bold text-lytix-teal-dark\",\"children\":\"Ruxotemitide (LTX-315)\"}]]}],[\"$\",\"p\",null,{\"className\":\"text-sm text-lytix-navy/85 ml-4\",\"children\":\"Neoadjuvant resectable melanoma\"}]]}],[\"$\",\"div\",null,{\"className\":\"col-span-4 px-2\",\"children\":[\"$\",\"div\",null,{\"className\":\"relative h-4 bg-lytix-ice rounded-full overflow-hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute inset-0 grid grid-cols-4 z-10 pointer-events-none\",\"children\":[[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}],[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}],[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}],[\"$\",\"span\",null,{}]]}],[\"$\",\"div\",null,{\"className\":\"pipeline-bar-fill absolute left-0 top-0 h-full w-[75%] bg-gradient-to-r from-lytix-teal via-lytix-teal to-lytix-cyan rounded-full overflow-hidden\",\"children\":[\"$\",\"span\",null,{\"className\":\"pipeline-shine\"}]}]]}]}],[\"$\",\"div\",null,{\"className\":\"text-center\",\"children\":[\"$\",\"span\",null,{\"className\":\"badge-shine inline-flex items-center justify-center px-3 py-1.5 rounded-full bg-lytix-coral/10 text-lytix-coral font-semibold text-xs border border-lytix-coral/20 text-center\",\"children\":\"Seeking Partners\"}]}]]}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-7 gap-4 items-center py-5 px-6 border-b border-lytix-ice hover:bg-lytix-light/50 transition-colors\",\"children\":[[\"$\",\"div\",null,{\"className\":\"col-span-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2 mb-1\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-2.5 h-2.5 rounded-full bg-lytix-navy-deep relative\",\"children\":[\"$\",\"span\",null,{\"className\":\"absolute inset-0 rounded-full bg-lytix-navy-deep animate-ping opacity-40\"}]}],[\"$\",\"p\",null,{\"className\":\"font-bold text-lytix-navy-deep\",\"children\":\"LTX-401\"}]]}],[\"$\",\"p\",null,{\"className\":\"text-sm text-lytix-navy/85 ml-4\",\"children\":\"Deep-seated solid tumors\"}]]}],[\"$\",\"div\",null,{\"className\":\"col-span-4 px-2\",\"children\":[\"$\",\"div\",null,{\"className\":\"relative h-4 bg-lytix-ice rounded-full overflow-hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute inset-0 grid grid-cols-4 z-10 pointer-events-none\",\"children\":[[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}],[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}],\"$L24\",\"$L25\"]}],\"$L26\"]}]}],\"$L27\"]}],\"$L28\"]}]}],\"$L29\"]}],\"$L2a\",\"$L2b\"]}]]}]}]\n"])</script>
1<script>self.__next_f.push([1,"21:[\"$\",\"section\",null,{\"className\":\"py-16 md:py-32 bg-navy-gradient text-white relative overflow-hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute inset-0 tech-grid opacity-10\"}],[\"$\",\"div\",null,{\"className\":\"absolute top-0 right-0 w-1/2 h-full bg-gradient-to-l from-lytix-teal/10 to-transparent\"}],[\"$\",\"div\",null,{\"className\":\"container mx-auto px-4 lg:px-8 relative z-10\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-12 animate-slide-left\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-12 h-1 bg-lytix-cyan rounded-full mb-4\"}],[\"$\",\"span\",null,{\"className\":\"text-xl md:text-2xl font-black uppercase tracking-[0.25em] text-lytix-cyan block\",\"children\":\"Clinical Trials\"}]]}],[\"$\",\"div\",null,{\"className\":\"grid lg:grid-cols-2 gap-8 lg:gap-20 items-center\",\"children\":[[\"$\",\"div\",null,{\"className\":\"space-y-6 animate-slide-left stagger-1\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"text-4xl md:text-5xl lg:text-6xl font-bold leading-tight\",\"children\":[\"Learn More About Our Deep \",[\"$\",\"span\",null,{\"className\":\"text-lytix-cyan\",\"children\":\"Clinical Trial Validation\"}]]}],[\"$\",\"p\",null,{\"className\":\"text-lg text-white/90 leading-relaxed\",\"children\":\"Lytix Biopharma has completed multiple Phase 2 trials, and is currently enrolling patients in an investigator-led Phase 2 study, NeoLIPA which is evaluating ruxotemitide (formerly LTX-315) in combination with pembrolizumab in resectable melanoma patients in the neoadjuvant setting.\"}],[\"$\",\"$Lc\",null,{\"href\":\"/clinical-trials\",\"children\":[\"$\",\"button\",null,{\"data-slot\":\"button\",\"data-variant\":\"default\",\"data-size\":\"lg\",\"className\":\"inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium disabled:pointer-events-none disabled:opacity-50 [\u0026_svg]:pointer-events-none [\u0026_svg:not([class*='size-'])]:size-4 shrink-0 [\u0026_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive h-10 rounded-md px-6 has-[\u003esvg]:px-4 bg-lytix-teal hover:bg-lytix-cyan hover:text-lytix-navy text-white shadow-lg hover:shadow-xl transition-all hover:scale-[1.02]\",\"children\":[\"Explore Clinical Trials\",[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-arrow-right ml-2 h-5 w-5\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"1ays0h\",{\"d\":\"M5 12h14\"}],[\"$\",\"path\",\"xquz4c\",{\"d\":\"m12 5 7 7-7 7\"}],\"$undefined\"]}]]}]}]]}],[\"$\",\"div\",null,{\"className\":\"animate-slide-right stagger-2\",\"children\":[\"$\",\"div\",null,{\"className\":\"relative rounded-2xl overflow-hidden shadow-2xl border border-white/10 group hover:shadow-lytix-cyan/20 hover:shadow-3xl transition-all duration-500\",\"children\":[[\"$\",\"$Ld\",null,{\"src\":\"/images/orb 1.webp\",\"alt\":\"Scientific visualization\",\"width\":800,\"height\":500,\"className\":\"w-full h-auto object-cover group-hover:scale-105 transition-transform duration-700\"}],[\"$\",\"div\",null,{\"className\":\"absolute inset-0 bg-gradient-to-tr from-lytix-cyan/20 to-transparent opacity-0 group-hover:opacity-100 transition-opacity duration-500\"}]]}]}]]}]]}]]}]\n"])</script>
1<script>self.__next_f.push([1,"22:[\"$\",\"section\",null,{\"className\":\"py-16 md:py-32 bg-white relative z-[2]\",\"children\":[\"$\",\"div\",null,{\"className\":\"container mx-auto px-4 lg:px-8\",\"children\":[\"$\",\"div\",null,{\"className\":\"grid lg:grid-cols-2 gap-8 lg:gap-20 items-center\",\"children\":[[\"$\",\"div\",null,{\"className\":\"order-2 lg:order-1 animate-slide-left stagger-2\",\"children\":[\"$\",\"div\",null,{\"className\":\"relative rounded-2xl overflow-hidden shadow-2xl group hover:shadow-3xl transition-shadow duration-500\",\"children\":[\"$\",\"$Ld\",null,{\"src\":\"/images/doctor hero.webp\",\"alt\":\"Medical professional - Partnership opportunities\",\"width\":800,\"height\":500,\"className\":\"w-full h-auto object-cover group-hover:scale-105 transition-transform duration-700\"}]}]}],[\"$\",\"div\",null,{\"className\":\"order-1 lg:order-2 space-y-6 animate-slide-right stagger-1\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-14\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-12 h-1 bg-lytix-teal rounded-full mb-4\"}],[\"$\",\"span\",null,{\"className\":\"text-xl md:text-2xl font-black uppercase tracking-[0.25em] text-lytix-teal-dark block\",\"children\":\"Partnerships\"}]]}],[\"$\",\"h2\",null,{\"className\":\"text-4xl md:text-5xl lg:text-6xl font-bold leading-tight text-lytix-navy\",\"children\":[\"Our Partnering Strategy is Built to Deliver \",[\"$\",\"span\",null,{\"className\":\"text-lytix-coral\",\"children\":\"Commercial Success\"}]]}],[\"$\",\"p\",null,{\"className\":\"text-lg text-lytix-navy/90 leading-relaxed\",\"children\":\"Interested in learning more about our assets? At Lytix Biopharma we are open to discussions on co-development and outlicensing opportunities.\"}],[\"$\",\"div\",null,{\"className\":\"p-6 rounded-xl bg-gradient-to-br from-lytix-ice to-white border border-lytix-teal/20 hover:border-lytix-teal/40 hover:shadow-lg transition-all duration-300\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2 mb-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-2 h-2 rounded-full bg-lytix-teal animate-pulse\"}],[\"$\",\"h4\",null,{\"className\":\"font-semibold text-lg text-lytix-navy\",\"children\":\"Current Partnership\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-center py-3 mb-4 bg-white rounded-lg border border-lytix-ice\",\"children\":[\"$\",\"$Ld\",null,{\"src\":\"/images/verrica-logo.png\",\"alt\":\"Verrica Pharmaceuticals\",\"width\":180,\"height\":70,\"className\":\"h-auto w-[160px] object-contain\"}]}],[\"$\",\"p\",null,{\"className\":\"text-lytix-navy/90 mb-3 text-sm leading-relaxed\",\"children\":[\"Dermatology indications only. Completed Phase 2 study of ruxotemitide (LTX-315, VP-315) in basal cell carcinoma with \",[\"$\",\"strong\",null,{\"className\":\"text-lytix-navy\",\"children\":\"51% complete response rate\"}],\".\"]}],[\"$\",\"a\",null,{\"href\":\"https://newsweb.oslobors.no/message/659147\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"inline-flex items-center text-lytix-coral hover:text-lytix-raspberry font-medium transition-colors group/link text-sm\",\"children\":[\"See latest positive results\",[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-external-link ml-2 h-4 w-4 group-hover/link:rotate-12 transition-transform\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"1q9fwt\",{\"d\":\"M15 3h6v6\"}],[\"$\",\"path\",\"gplh6r\",{\"d\":\"M10 14 21 3\"}],[\"$\",\"path\",\"a6xqqp\",{\"d\":\"M18 13v6a2 2 0 0 1-2 2H5a2 2 0 0 1-2-2V8a2 2 0 0 1 2-2h6\"}],\"$undefined\"]}]]}]]}],[\"$\",\"$Lc\",null,{\"href\":\"/partnerships\",\"children\":[\"$\",\"button\",null,{\"data-slot\":\"button\",\"data-variant\":\"link\",\"data-size\":\"default\",\"className\":\"inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md font-medium transition-all disabled:pointer-events-none disabled:opacity-50 [\u0026_svg]:pointer-events-none [\u0026_svg:not([class*='size-'])]:size-4 shrink-0 [\u0026_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive underline-offset-4 hover:underline h-9 py-2 has-[\u003esvg]:px-3 px-0 text-lytix-teal-dark hover:text-lytix-teal text-lg group/btn\",\"children\":[\"Learn About Partnerships\",\"$L2c\"]}]}]]}]]}]}]}]\n"])</script>
1<script>self.__next_f.push([1,"23:[\"$\",\"section\",null,{\"className\":\"py-16 md:py-32 bg-lytix-light relative overflow-hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute inset-0 molecular-pattern opacity-30\"}],[\"$\",\"div\",null,{\"className\":\"container mx-auto px-4 lg:px-8 relative z-10\",\"children\":[[\"$\",\"div\",null,{\"className\":\"text-center max-w-3xl mx-auto mb-16 space-y-4 animate-fade-up stagger-1\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mb-14 flex flex-col items-center\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-12 h-1 bg-lytix-teal rounded-full mb-4\"}],[\"$\",\"span\",null,{\"className\":\"text-xl md:text-2xl font-black uppercase tracking-[0.25em] text-lytix-teal-dark block -mr-[0.25em]\",\"children\":\"News\"}]]}],[\"$\",\"h2\",null,{\"className\":\"text-4xl md:text-5xl lg:text-6xl font-bold leading-tight text-lytix-navy\",\"children\":\"Latest Press Releases\"}]]}],[\"$\",\"div\",null,{\"className\":\"grid md:grid-cols-3 gap-6 mb-12\",\"children\":[[\"$\",\"div\",\"0\",{\"data-slot\":\"card\",\"className\":\"text-card-foreground flex flex-col gap-6 rounded-xl border py-6 shadow-sm card-hover border-lytix-ice bg-white group animate-scale-up stagger-1\",\"children\":[[\"$\",\"div\",null,{\"data-slot\":\"card-header\",\"className\":\"@container/card-header grid auto-rows-min grid-rows-[auto_auto] items-start gap-2 px-6 has-data-[slot=card-action]:grid-cols-[1fr_auto] [.border-b]:pb-6\",\"children\":[[\"$\",\"div\",null,{\"data-slot\":\"card-description\",\"className\":\"text-sm text-lytix-navy/80\",\"children\":\"Sep 3, 2026\"}],[\"$\",\"div\",null,{\"data-slot\":\"card-title\",\"className\":\"font-semibold text-lg leading-tight text-lytix-navy group-hover:text-lytix-teal-dark transition-colors duration-300\",\"children\":\"Lytix Biopharma ASA: Grant of share options to management and key personnel\"}]]}],[\"$\",\"div\",null,{\"data-slot\":\"card-content\",\"className\":\"px-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-lytix-navy/85 text-sm line-clamp-3 mb-4\",\"children\":\"Lytix Biopharma ASA: Grant of share options to management and key personnel\"}],[\"$\",\"a\",null,{\"href\":\"https://newsweb.oslobors.no/message/681627\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"inline-flex items-center text-lytix-teal-dark hover:text-lytix-teal font-medium text-sm group/link\",\"children\":[\"Read More\",[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-chevron-right ml-1 h-4 w-4 group-hover/link:translate-x-1 transition-transform\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"mthhwq\",{\"d\":\"m9 18 6-6-6-6\"}],\"$undefined\"]}]]}]]}]]}],[\"$\",\"div\",\"1\",{\"data-slot\":\"card\",\"className\":\"text-card-foreground flex flex-col gap-6 rounded-xl border py-6 shadow-sm card-hover border-lytix-ice bg-white group animate-scale-up stagger-2\",\"children\":[[\"$\",\"div\",null,{\"data-slot\":\"card-header\",\"className\":\"@container/card-header grid auto-rows-min grid-rows-[auto_auto] items-start gap-2 px-6 has-data-[slot=card-action]:grid-cols-[1fr_auto] [.border-b]:pb-6\",\"children\":[[\"$\",\"div\",null,{\"data-slot\":\"card-description\",\"className\":\"text-sm text-lytix-navy/80\",\"children\":\"Sep 2, 2026\"}],[\"$\",\"div\",null,{\"data-slot\":\"card-title\",\"className\":\"font-semibold text-lg leading-tight text-lytix-navy group-hover:text-lytix-teal-dark transition-colors duration-300\",\"children\":\"Lytix Biopharma ASA: Mandatory notification of trade by primary insider\"}]]}],[\"$\",\"div\",null,{\"data-slot\":\"card-content\",\"className\":\"px-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-lytix-navy/85 text-sm line-clamp-3 mb-4\",\"children\":\"Lytix Biopharma ASA: Mandatory notification of trade by primary insider\"}],[\"$\",\"a\",null,{\"href\":\"https://newsweb.oslobors.no/message/681499\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"inline-flex items-center text-lytix-teal-dark hover:text-lytix-teal font-medium text-sm group/link\",\"children\":[\"Read More\",\"$L2d\"]}]]}]]}],\"$L2e\"]}],\"$L2f\"]}]]}]\n"])</script>
1<script>self.__next_f.push([1,"24:[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}]\n25:[\"$\",\"span\",null,{}]\n26:[\"$\",\"div\",null,{\"className\":\"pipeline-bar-fill absolute left-0 top-0 h-full w-[21%] bg-gradient-to-r from-lytix-teal to-lytix-cyan rounded-full overflow-hidden\",\"style\":{\"animationDelay\":\"0.3s\"},\"children\":[\"$\",\"span\",null,{\"className\":\"pipeline-shine\"}]}]\n27:[\"$\",\"div\",null,{\"className\":\"text-center\",\"children\":[\"$\",\"span\",null,{\"className\":\"badge-shine inline-flex items-center px-3 py-1.5 rounded-full bg-lytix-coral/10 text-lytix-coral font-semibold text-xs border border-lytix-coral/20\",\"children\":\"Seeking Partners\"}]}]\n28:[\"$\",\"div\",null,{\"className\":\"grid grid-cols-7 gap-4 items-center py-5 px-6 border-b border-lytix-ice\",\"children\":[[\"$\",\"div\",null,{\"className\":\"col-span-2\",\"children\":[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2 mb-1\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-2.5 h-2.5 rounded-full bg-lytix-teal/50\"}],[\"$\",\"p\",null,{\"className\":\"font-bold text-lytix-teal-dark/60\",\"children\":\"More Pipeline Assets...\"}]]}]}],[\"$\",\"div\",null,{\"className\":\"col-span-4 px-2\",\"children\":[\"$\",\"div\",null,{\"className\":\"h-4 bg-lytix-ice rounded-full\"}]}],[\"$\",\"div\",null,{\"className\":\"text-center\"}]]}]\n"])</script>
1<script>self.__next_f.push([1,"29:[\"$\",\"div\",null,{\"className\":\"md:hidden flex flex-col gap-4 bg-white rounded-t-2xl border-2 border-b-0 border-lytix-ice shadow-xl p-4 sm:p-6 pb-24\",\"children\":[[\"$\",\"div\",null,{\"className\":\"border-2 border-lytix-ice rounded-xl p-5 bg-gradient-to-br from-white to-lytix-light shadow-sm\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-col gap-3 mb-4\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2 mb-1\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-2.5 h-2.5 rounded-full bg-lytix-teal relative flex-shrink-0\",\"children\":[\"$\",\"span\",null,{\"className\":\"absolute inset-0 rounded-full bg-lytix-teal animate-ping opacity-40\"}]}],[\"$\",\"p\",null,{\"className\":\"font-bold text-lytix-teal-dark text-lg leading-tight\",\"children\":\"Ruxotemitide (LTX-315)\"}]]}],[\"$\",\"p\",null,{\"className\":\"text-sm text-lytix-navy/85 ml-4\",\"children\":\"Neoadjuvant resectable melanoma\"}]]}],[\"$\",\"div\",null,{\"className\":\"ml-4\",\"children\":[\"$\",\"span\",null,{\"className\":\"badge-shine inline-flex items-center justify-center px-3 py-1 rounded-full bg-lytix-coral/10 text-lytix-coral font-semibold text-xs border border-lytix-coral/20\",\"children\":\"Seeking Partners\"}]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-5 bg-white p-3 rounded-lg border border-lytix-ice\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex justify-between text-[10px] font-bold text-lytix-navy/60 uppercase tracking-wider mb-2 px-1\",\"children\":[[\"$\",\"span\",null,{\"children\":\"Pre\"}],[\"$\",\"span\",null,{\"children\":\"I\"}],[\"$\",\"span\",null,{\"children\":\"II\"}],[\"$\",\"span\",null,{\"children\":\"III\"}]]}],[\"$\",\"div\",null,{\"className\":\"relative h-4 bg-lytix-ice rounded-full overflow-hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute inset-0 grid grid-cols-4 z-10 pointer-events-none\",\"children\":[[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}],[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}],[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}],[\"$\",\"span\",null,{}]]}],[\"$\",\"div\",null,{\"className\":\"pipeline-bar-fill absolute left-0 top-0 h-full w-[75%] bg-gradient-to-r from-lytix-teal via-lytix-teal to-lytix-cyan rounded-full overflow-hidden\",\"children\":[\"$\",\"span\",null,{\"className\":\"pipeline-shine\"}]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"border-2 border-lytix-ice rounded-xl p-5 bg-gradient-to-br from-white to-lytix-light shadow-sm\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-col gap-3 mb-4\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2 mb-1\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-2.5 h-2.5 rounded-full bg-lytix-navy-deep relative flex-shrink-0\",\"children\":[\"$\",\"span\",null,{\"className\":\"absolute inset-0 rounded-full bg-lytix-navy-deep animate-ping opacity-40\"}]}],[\"$\",\"p\",null,{\"className\":\"font-bold text-lytix-navy-deep text-lg leading-tight\",\"children\":\"LTX-401\"}]]}],[\"$\",\"p\",null,{\"className\":\"text-sm text-lytix-navy/85 ml-4\",\"children\":\"Deep-seated solid tumors\"}]]}],[\"$\",\"div\",null,{\"className\":\"ml-4\",\"children\":[\"$\",\"span\",null,{\"className\":\"badge-shine inline-flex items-center px-3 py-1 rounded-full bg-lytix-coral/10 text-lytix-coral font-semibold text-xs border border-lytix-coral/20\",\"children\":\"Seeking Partners\"}]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-5 bg-white p-3 rounded-lg border border-lytix-ice\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex justify-between text-[10px] font-bold text-lytix-navy/60 uppercase tracking-wider mb-2 px-1\",\"children\":[[\"$\",\"span\",null,{\"children\":\"Pre\"}],[\"$\",\"span\",null,{\"children\":\"I\"}],[\"$\",\"span\",null,{\"children\":\"II\"}],[\"$\",\"span\",null,{\"children\":\"III\"}]]}],[\"$\",\"div\",null,{\"className\":\"relative h-4 bg-lytix-ice rounded-full overflow-hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute inset-0 grid grid-cols-4 z-10 pointer-events-none\",\"children\":[[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}],[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}],[\"$\",\"span\",null,{\"className\":\"border-r-2 border-white\"}],[\"$\",\"span\",null,{}]]}],[\"$\",\"div\",null,{\"className\":\"pipeline-bar-fill absolute left-0 top-0 h-full w-[21%] bg-gradient-to-r from-lytix-teal to-lytix-cyan rounded-full overflow-hidden\",\"style\":{\"animationDelay\":\"0.3s\"},\"children\":\"$L30\"}]]}]]}]]}],\"$L31\"]}]\n"])</script>
1<script>self.__next_f.push([1,"2a:[\"$\",\"div\",null,{\"className\":\"absolute bottom-0 left-0 right-0 h-32 bg-gradient-to-t from-white via-white to-transparent pointer-events-none\"}]\n2b:[\"$\",\"div\",null,{\"className\":\"absolute bottom-0 left-0 right-0 flex justify-center pb-2 z-10\",\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/pipeline\",\"children\":[\"$\",\"button\",null,{\"data-slot\":\"button\",\"data-variant\":\"default\",\"data-size\":\"lg\",\"className\":\"inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium disabled:pointer-events-none disabled:opacity-50 [\u0026_svg]:pointer-events-none [\u0026_svg:not([class*='size-'])]:size-4 shrink-0 [\u0026_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive bg-primary hover:bg-primary/90 h-10 rounded-md px-6 has-[\u003esvg]:px-4 btn-lytix-gradient text-white shadow-xl hover:shadow-2xl hover:scale-105 transition-all\",\"children\":[\"View Full Pipeline\",[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-arrow-right ml-2 h-5 w-5\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"1ays0h\",{\"d\":\"M5 12h14\"}],[\"$\",\"path\",\"xquz4c\",{\"d\":\"m12 5 7 7-7 7\"}],\"$undefined\"]}]]}]}]}]\n2c:[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-chevron-right ml-1 h-5 w-5 group-hover/btn:translate-x-2 transition-transform duration-300\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"mthhwq\",{\"d\":\"m9 18 6-6-6-6\"}],\"$undefined\"]}]\n2d:[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-chevron-right ml-1 h-4 w-4 group-hover/link:translate-x-1 transition-transform\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"mthhwq\",{\"d\":\"m9 18 6-6-6-6\"}],\"$undefined\"]}]\n"])</script>
1<script>self.__next_f.push([1,"2e:[\"$\",\"div\",\"2\",{\"data-slot\":\"card\",\"className\":\"text-card-foreground flex flex-col gap-6 rounded-xl border py-6 shadow-sm card-hover border-lytix-ice bg-white group animate-scale-up stagger-3\",\"children\":[[\"$\",\"div\",null,{\"data-slot\":\"card-header\",\"className\":\"@container/card-header grid auto-rows-min grid-rows-[auto_auto] items-start gap-2 px-6 has-data-[slot=card-action]:grid-cols-[1fr_auto] [.border-b]:pb-6\",\"children\":[[\"$\",\"div\",null,{\"data-slot\":\"card-description\",\"className\":\"text-sm text-lytix-navy/80\",\"children\":\"Aug 26, 2026\"}],[\"$\",\"div\",null,{\"data-slot\":\"card-title\",\"className\":\"font-semibold text-lg leading-tight text-lytix-navy group-hover:text-lytix-teal-dark transition-colors duration-300\",\"children\":\"Lytix Biopharma Q2 2026: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma, Marking Defining Milestone\"}]]}],[\"$\",\"div\",null,{\"data-slot\":\"card-content\",\"className\":\"px-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-lytix-navy/85 text-sm line-clamp-3 mb-4\",\"children\":\"Lytix Biopharma Q2 2026: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma, Marking Defining Milestone\"}],[\"$\",\"a\",null,{\"href\":\"https://newsweb.oslobors.no/message/680938\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"inline-flex items-center text-lytix-teal-dark hover:text-lytix-teal font-medium text-sm group/link\",\"children\":[\"Read More\",[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-chevron-right ml-1 h-4 w-4 group-hover/link:translate-x-1 transition-transform\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"mthhwq\",{\"d\":\"m9 18 6-6-6-6\"}],\"$undefined\"]}]]}]]}]]}]\n"])</script>
1<script>self.__next_f.push([1,"2f:[\"$\",\"div\",null,{\"className\":\"text-center animate-fade-up stagger-5\",\"children\":[\"$\",\"$Lc\",null,{\"href\":\"/news\",\"children\":[\"$\",\"button\",null,{\"data-slot\":\"button\",\"data-variant\":\"outline\",\"data-size\":\"lg\",\"className\":\"inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium disabled:pointer-events-none disabled:opacity-50 [\u0026_svg]:pointer-events-none [\u0026_svg:not([class*='size-'])]:size-4 shrink-0 [\u0026_svg]:shrink-0 outline-none focus-visible:border-ring focus-visible:ring-ring/50 focus-visible:ring-[3px] aria-invalid:ring-destructive/20 dark:aria-invalid:ring-destructive/40 aria-invalid:border-destructive bg-background shadow-xs dark:bg-input/30 dark:border-input dark:hover:bg-input/50 h-10 rounded-md px-6 has-[\u003esvg]:px-4 border-2 border-lytix-teal text-lytix-teal-dark hover:bg-lytix-teal hover:text-white hover:scale-[1.02] transition-all\",\"children\":[\"View All Press Releases\",[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-arrow-right ml-2 h-5 w-5\",\"aria-hidden\":\"true\",\"children\":[[\"$\",\"path\",\"1ays0h\",{\"d\":\"M5 12h14\"}],[\"$\",\"path\",\"xquz4c\",{\"d\":\"m12 5 7 7-7 7\"}],\"$undefined\"]}]]}]}]}]\n"])</script>
1<script>self.__next_f.push([1,"30:[\"$\",\"span\",null,{\"className\":\"pipeline-shine\"}]\n31:[\"$\",\"div\",null,{\"className\":\"border border-lytix-ice rounded-xl p-5 bg-lytix-light/30 opacity-40\",\"children\":[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-2.5 h-2.5 rounded-full bg-lytix-teal/50\"}],[\"$\",\"p\",null,{\"className\":\"font-bold text-lytix-teal-dark/60\",\"children\":\"More Pipeline Assets...\"}]]}]}]\n"])</script>
1</body></html>
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.